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Abstract 
 
Breast cancer is one of the major health problems worldwide and it is the second cause of 
cancer-related in women. Patients often develop resistance to the current therapies. For this 
reason, the identification of new specific clinical molecular markers and pharmacologic 
targets in cancer research is an ongoing challenge. Over the last years, microRNAs (miRNAs) 
have become one of the main subjects of study in the area of cancer genomics. They 
negatively regulate gene expression post-transcriptional by inhibiting translation and causing 
degradation of target mRNA. More than a thousand miRNAs exist in the human genome and 
each one can potentially regulate hundreds of mRNAs. By regulating the expression of target 
genes, miRNAs can have a tumor suppressor or oncogenic role. Therefore, miRNAs can play 
an important role in all the phases of cancer, like as initiation, progression, growth, apoptosis, 
invasion and metastasis.  
In a previous study based on miRNA profiling, in different solid tumors, comprised breast 
cancer, and normal tissues, several miRNA were reported to be over- or down-regulated in 
solid tumors in comparison to normal tissues (Volinia et al. Genome Res. 2010). In other 
scientific reports other miRNAs were positively or negatively correlated with tumor 
progression (Volinia S. and Croce CM. PNAS 2013). 
Starting from these literature data, we decided to analyze the in vitro effect of the 
administration of this tumor-related miRNAs in order to verify their effect on the viability and 
transcriptional regulation in breast cancer cell line, in order to gain experimental evidences on 
their actual involvement in the tumor illness.  
Firstly, we have chosen 10 different cell lines of breast cancer origin (MCF-7, MDA-MB-231, 
MDA-MB-468, MDA-MB-361, SKBR3, T47D, BT474, ZR75.1, MDA-MB-453, HBL-100) 
and on 2 cell lines of breast normal epithelium (MCF10A and 184A1). Genomic analysis 
revealed presence of a complex panel of cancer-related mutations, and the cell lines were 
different in term of cell growth. We checked also the miRNA levels inside cell lines.  
Two groups of primary solid tumor-related (23 miRNAs: hsa-miR-126*, hsa-let-7d*, hsa-
miR-326, hsa-miR-320c , hsa-miR-302a , hsa-miR-222, hsa-miR-218, hsa-miR-210, hsa-miR-
206, hsa-miR-203, hsa-miR-202, hsa-miR-181a , hsa-miR-142, hsa-miR-145, hsa-miR-143, 
hsa-miR-138, hsa-miR-130b , hsa-miR-126, hsa-miR-99a , hsa-miR-28-5p , hsa-miR-33b , 
hsa-miR-26b , hsa-miR-21) or progression-related (15 miRNAs: hsa-miR-9, hsa-miR-10a, 
hsa-miR-25, hsa-miR-27, hsa-miR-30a, hsa-miR-93, hsa-miR-103, hsa-miR-148b, hsa-miR-
151, hsa-miR-301a, hsa-miR-328, hsa-miR-484, hsa-miR-615, hsa-miR-874, hsa-miR-1307) 
miRNAs were transiently transfected into cells, and viability was assessed. We were able to 
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experimentally identify two groups of miRNAs which were able to significantly increase or 
decrease cell viability. The miRNAs that showed to increase cellular viability in five out 
twelve cell lines were: miR-130b, miR-138, miR-210, miR-148b and miR-1307. On the other 
hand, mirR-93, miR-126 and miR-145 displayed a significant inhibitory effect on cell 
viability in five out twelve cell lines. These miRNAs were further investigated for their 
capacity to affect cell migration,  cell invasion, and genome profiling.  
The main outcome of our work has been the identification from a wide list of cancer-related 
miRNAs of few of them involved in the in vitro regulation of cell growth and invasion. As a 
first attempt to identify target genes commonly regulated in vivo and in vitro, we have 
bioinformatically identified, in a first not exhaustive screening, PTEN and DICER1 genes, 
which in vivo and in vitro negatively correlated  with miR-210 and miR-130b, respectively. 
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1. Introduction 
      1.1. Cancer 
 
Cancer is the result of many complex changes occurring in a “normal” cell, progressing 
through to malignant and potentially metastatic. The 6 hallmarks of cancer as outlined in 
Hanahan and Weinburg’s review (1) are shown below (Figure 1). Cells commonly become 
cancerous when they acquire irreparable DNA damage, changing the sequence of genes which 
code for important regulatory proteins. After replication the mutations are passed down to the 
next generation of cells which can lead to deregulated growth, tumor progression and invasion 
through the basement membrane. 
 
 
Figure 1. The 6 hallmarks of cancer. 
 
Accumulations of successive DNA mutations arise over the course of a person’s life time 
(somatic gene changes) which is why age is often a risk factor in cancer. Also, lifestyle 
factors such as diet, alcohol, stress and tobacco, have all been implicated in either causing or 
increasing the risk of cancer. The environmental exposure to chemical carcinogens and the 
ultra-violet rays of the sun have also been shown to result in DNA damage and result in 
cancer. There are examples of gene mutations that are hereditary for instance BRCA1 and 
BRCA2 which are tumor suppressor genes involved in DNA repair of double stranded breaks. 
Mutations in these genes can cause instability of the human genome. Women that have 
heterozygous germ-line mutations in BRCA1 or BRCA2 have a substantially increased risk of 
highly penetrative breast cancer and ovarian cancer. Patients that are positive for this mutation 
can chose to have pre-emptive mastectomies or preventative Tamoxifen treatment (2). 
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1.2. Breast Cancer 
 
Breast cancer (BC) is a complex and heterogeneous disease, characterized by variant genetic 
alterations and distinct morphologic and molecular features. Despite common 
histopathological features at diagnosis, BC is noted for disparate clinical behaviors and patient 
outcomes.
 
The heterogeneity observed among breast cancer reflects the now well accepted 
notion that is not just one disease, but that instead represents a collection of distinct neoplastic 
diseases of the breast and the cells composing the breast (3).
 
The character and nature of this 
diseases can be made through traditional pathological and morphological examination, but 
only through molecular analyses can be appreciated the extent of diversity among breast 
cancer. Breast carcinomas can be divided into two major groups: 
 In situ Carcinomas - the tumor cells remain confined to the ducts or lobules and show 
no evidence of microscopic invasion into the surrounding breast stroma. There are two 
types of in-situ carcinoma; ductal and lobular, named according to the predominant 
cell type from which the tumour arises. 
 Invasive carcinoma - the tumor cells invade the breast stroma and have the potential to 
metastasize to distant sites. The invasive breast carcinomas consist of several 
histological subtypes; the commonest being infiltrating ductal adenocarcinoma (75-
80%), followed in frequency by invasive lobular (10-15%), Mixed ductal-lobular 
(<5%), Inflammatory (2-3%), Colloid (2-3%), Tubular (<2%), Medullary (<2%), and 
Papillary (1%) 5. Rarer subtypes, including metaplastic breast cancer and invasive 
micropapillary breast cancer, all account for less than 5 percent of cases overall. 
 
 
Breast Cancer is a major health problem in the United States and worldwide, it is now the 
second cause of cancer-related in women (second only to lung cancer) with approximately 
40,030 death expected in 2013 for both men and women (or 39,620 deaths among women, 
representing 14% of all cancer-related deaths among women) and the vast majority of breast 
cancer-related deaths involve metastatic disease. Metastasis is a multistep process which 
consists of a cell: - detaching ang migrating out of the primary tumor site; - invading the 
basement membrane to enter the circulatory system (intravasation); - surviving cell 
detachment-mediated apoptosis (anoikis); - exiting circulatory vessels at the metastatic site 
(extravasation); and – adapt into a new environment and soil a metastatic tumor. Breast cancer 
is about 100 times more common in women than in men although males tend to have poorer 
outcomes due to delays in diagnosis. The American Cancer Society estimates that 232,340 
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new cases of invasive ductal breast cancer (IDC) and 64,640 new cases of ductal carcinoma in 
situ (DCIS) will be diagnosed among women in the United States in 2013. Invasive breast 
cancer accounts for 29% of all cancer diagnoses among women in the United States and 23% 
of all cancer diagnoses among women worldwide. In the worldwide there is an estimated 
1,383,500 new cases of BC will be diagnosed in women in 2013 (4).
 
As such, this disease 
represents one of the most serious and costly health issues. The incidence of breast cancer 
increases with age (around 80% of diagnosed cases are in women over the age of 50) and 
there are other risk factors; such as obesity, high socio-economic group, alcohol use, 
expression of BRCA1 or BRCA2, ethnicity, early menarche, and childbirth late in life.  A 
family history of breast cancer in female relatives has shown to be an important predisposing 
factor. In women, the breast cancer susceptibility genes BRCA1 and BRCA2 are thought to 
account for most hereditary breast cancers. Mutations in these genes confer a 40% to 70% risk 
for developing breast cancer by age 70 years. Other molecular markers are important in the 
pathogenesis and prognosis of breast cancer in women, as C-erbB-2, p53, Bcl-2, cyclin D1, 
and epidermal growth factor receptor (EGFR). The c-erbB-2 protooncogene encodes for a 
transmembrane receptor of the tyrosine kinase family, which is closely related to EGFR. This 
protein is expressed in 20% to 30% of breast cancers and may be associated with a poor 
prognosis. P53 is a tumor suppressor gene that controls cell growth by inducing cell cycle 
blockade, apoptosis, and cell differentiation. P53 gene alterations are the most common single 
genetic abnormality in breast cancer and are present in approximately 30% of cases. Bcl-2 is a 
protooncogene that inhibits apoptosis and thereby promotes cell growth. In breast cancer, 
expression of Bcl-2 has been associated with favorable prognostic features. Cyclin D1 is 
involved in cell-cycle regulation and helps control the cell’s entry into S phase. In breast 
cancer this gene is oncogenic but appears to be associated with a favorable prognosis. 
Epidermal growth factor receptor is a transmembrane glycoprotein that is present in low 
levels in normal breast tissue and is overexpressed in 35% to 60% of BC. Over expression of 
EGFR is inversely correlated with estrogen receptor expression and may be a negative 
prognostic factor. Significant prognostic factors are also axillary lymph node status, tumor 
size, histological grade and hormone receptor status, as estrogen receptor, progesterone 
receptor, and ErbB2, these are used to decide the treatment options for the patient. The patient 
can be classed as “triple negative” where they do not express any of these 3 receptors. 
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1.2.1. Breast Cancer development 
Breast Cancer develops over a long period of time and requires multiple molecular alterations. 
The time required for the process of carcinogenesis is not well established for any human 
cancer, estimates suggest that this multistep process unfolds over many years and possibly 
several decades. Generally, sporadic breast cancer, in which there is no recognizable strong 
genetic component, emerge later in life (reflecting mostly postmenopausal breast cancer), 
whereas hereditary breast cancers occur earlier in life (reflecting the contribution of genetic 
predisposition) (5). The main hypothesis for the natural history of breast cancer development 
is stepwise progression from atypical ductal hyperplasia to ductal carcinoma in situ (DCIS), 
followed by evolution of this pre-invasive lesion to invasive ductal breast cancer (IDC) 
(Figure 2). DCIS is by definition noninvasive, but can vary from low-grade to high-grade 
lesions that may contain invasive elements. For this reason, DCIS, especially if high grade, is 
a risk factor for development of IDC. Many IDC are associated with adjacent DCIS lesions. It 
is not entirely clear if DCIS is a required precursor for development of IDC, but many IDC at 
the time of diagnosis are accompanied by DCIS, and there is consensus that DCIS in the 
absence of intervention will progress to invasive disease. In the progression of the disease 
might occur genetic and epigenetic alterations between the altered cells of the different 
morphological stages that contributed at the development of the disease (6).
 
 Since the late 
1990s, invasive breast cancer have been characterized using gene expression analysis and 
classified on that basis into several molecular subtypes. Analyses of gene expression patterns 
between DCIS and IDC, have identified one correspondence in this two subtypes, this suggest 
that DCIS lesions are likely the direct precursors of invasive cancers. However, some recent 
molecular analysis suggest that the diversity of subtypes observed in invasive breast cancers 
derives from an evolution of low-grade to high-grade DCIS lesions.  
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Figure 2. Natural history of breast cancer development. Breast cancer develops from normal breast epithelial 
cells that evolve through atypical hyperplasia (and eventually dysplasia), DCIS, and invasive breast cancer. 
Multiple molecular alterations occur during this process, involving genetic and epigenetic alterations in 
precursor and neoplastic cells. Genetic predisposition can contribute to this process, but early molecular 
alterations (preceding DCIS) have not been well characterized. Original magnification, 20x. Modified from 
Rivenbark and Coleman (6),
 
with permission from Elsevier. 
 
 
1.3 Classification of Breast Cancer 
 
   1.3.1. Immunohistochemical classification of breast cancer 
 
The morphological subclassification of invasive ductal carcinomas is accomplished by 
histopathological immunostaining to detect the differential expression of protein biomarkers 
to provide a clinical classification for breast cancer and dictates therapeutic approaches for 
treatment. Routine histopathological subclassification is made for detect the expression of 
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth receptor 2 
(HER2; alias c-ErbB-2 or, in rodents, Neu), as well as HER1 and various cytokeratins (eg, 
CK5/6) (7). Approximately 70% of invasive breast cancers express ER, and the majority of 
ER
+ 
cancers also express PR. Although the presence of normal PR levels suggests an intact 
ER signal transduction pathway in the breast cancer cells, discrepant ER and PR expression 
patterns (ER
+
/PR
-
 and ER
-
/PR
+
) are sometimes observed, this may be attributable to false 
positive or false negative results, although technical improvements have reduced errors 
significantly. Collectively, the ER
+
 malignant neoplasms are classified as luminal cancers. 
These cancers are further subclassified based on their HER2 status and proliferation rate, 
giving rise  to the ER
+
/PR
+
/HER2
+
 and ER
+
/PR
+
/HER2
-
 subtypes. The ER
-
 breast cancer are 
subclassified as HER2
+
 and triple negative based on HER2 overexpression or gene 
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amplification status, basal cytokeratin expression, and EGFR (HER1) expression, giving rise 
to ER
-
/PR
-
/HER2
+
 (HER2-enriched) and ER
-
/PR
-
/HER2
-
 (triple negative) subtypes (Figure 3). 
 
 
 
 
 
Figure 3. Clinical classification of invasive breast cancer based on expression of ER, PR, and HER2. 
Representative examples of invasive breast cancers that correspond to the general clinical classifications are 
shown. Cancer histology is depicted using H&E staining; expression of ER, PR, and HER2 is visualized using 
immunohistochemistry. Breast cancers are generally classified as positive or negative for hormone receptors ER 
and PR and for HER2, resulting in four major clinical groupings: ER
+
/PR
+
/HER2
-
, ER
+
/PR
+
/HER2
+
, ER
-
/PR
-
/HER2
+
, and the triple-negative ER
-
/PR
-
/HER2
-
. Original magnification, 40x. 
 
   1.3.2. Molecular Classification of breast cancer: intrinsic subtypes 
 
Perou and Sorlie and colleagues (8) studied gene expression profiling using DNA microarrays 
have grouped breast cancer into 5 distinct molecular classes or intrinsic subtypes named: 
- Luminal A (ER+) 
- Luminal B (ER+/HER2-enriched) 
- Basal-like 
- HER2+-enriched 
- Normal-like 
More recently, a further subtypes have been identified: 
- Claudin-low 
Significantly, the molecular subtypes of breast cancer revealed by transcriptomic analysis are 
associated with different clinical outcomes. Although breast cancer classification methods 
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show good reproducibility, suggesting that these are robust biological subtypes, breast cancers 
that are not classifiable are identified with regular frequency (8).  
 
1.3.3. Luminal A and Luminal B Breast Cancers 
ER
+
 breast cancers occur most frequently and comprise two major molecular classifications: 
Luminal A and Luminal B. 
Luminal A is the more abundant subtypes and accounts for 40-60% of breast cancer. 
Predominantly is ER
+
/PR
+
/HER2
-
, with low histological grade and low expression of 
proliferative genes. This subtype is associated with lower relapse rate and longer survival, 
compared with the other subtypes. The TP53 pathway is conserved and the management of 
this tumors is centered on antiendocrine therapies because this subtype is poor responsive to 
chemotherapy. 
Luminal B subtype accounts for 15% of breast cancers, as luminal A is predominantly ER
+ 
although it has lower expression of ER-related genes and it is histological high grade with 
variable PR and HER2 status. Luminal B tumors in contrast with luminal A are more 
aggressive, with poorer prognosis. The TP53 pathway is frequently inactivated. Although 
luminal B tumors are ER
+
, a significant number do not respond to antiestrogen therapy but 
show greater response to chemotherapy. 
In general, the two ER
+
 breast cancer subtypes, Luminal A and Luminal B, are associated 
with a good prognosis and excellent long-term survival, whereas the ER
-
 subtypes (HER2
+
 
and basal-like) are difficult to treat and are associated with poor prognosis. 
 
1.3.4. HER2
+
 Enriched 
The HER2 gene, also known as HER2/neu or c-erbB2, is located on chromosome 17q. It is a 
proto-oncogene, a normal gene with the potential to become an oncogene as a result of 
molecular alterations like mutation, amplification or overexpression of its protein product. 
HER2 is a member of the human epidermal growth factor receptor family, a family of 
tyrosine kinases, which normally regulate a series of cellular processes, such as proliferation 
and growth. HER2 is notable for its role in the pathogenesis of breast cancer and as a target of 
treatment. It is a cell membrane surface-bound receptor tyrosine kinase and is normally 
involved in the signal transduction pathways leading to cell growth and differentiation. HER2 
is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. 
However, ErbB receptors dimerise on ligand binding, and HER2 is the preferential 
dimerization partner of other members of the ErbB family (9). 
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The HER2
+
-enriched subtype represent approximately 17% of all breast cancers. It is 
characterized by high expression of HER2 and related genes and it has high genomic 
instability. HER2 overexpression in breast cancer is associated with poor clinical outcomes, 
but it is also predictive of positive therapeutic responses to anti-HER2 drugs (eg, monoclonal 
antibody trastuzumab). HER2
+
 breast cancer are typically ER
-
, so the treatment for these 
cancers does not include anti-estrogenic hormonal therapies. 
 
1.3.5. Basal-like and Claudin-Low 
Basal-like and Claudin-low together represent subsets of triple negative breast cancers, 
lacking expression of ER and PR and also lacking amplification of HER2. These tumors 
represent 10% to 25% of breast cancers, they are highly proliferative and express genes 
characteristic of normal breast myoepithelial cells, such as cytokeratins 5, 6, and 17, and 
epidermal growth factor receptor (EGFR). They have a high rate of p53 mutations and are 
associated with increased genetic complexity. Not all tumors with basal-like gene expression 
profile are triple negative; 15% to 45% express ER and HER2 or both. The basal-like breast 
cancer have high rates of cell proliferation and extremely poor clinical outcomes. These 
cancers are associated with distinct risk factors, including early-onset menarche, younger age 
at first full-term pregnancy, and abdominal adiposity. Basal-like breast cancers have been 
shown to be over-represented in patients of certain age and ethnic groups, specifically young 
Black women (10). Claudin-low subtype breast cancer is enriched for markers of epithelial-to-
mesenchymal transition (EMT) and stem cell-like and/or tumor-initiating cell features. 
Although these tumors are chemo responsive, they have shown a poor prognosis across 
several studies. 
 
1.3.6. Normal-like 
The normal-like represents 3% to 10% of breast cancers, it is frequently ER
+
 and has low 
levels of proliferative genes and low tumor cellular. The normal-like breast cancers are so 
designated because they tend to cluster closely with normal breast epithelium in microarray 
studies. It is not yet clear whether this is a distinct molecular subtype of breast cancer or 
simply a grouping of breast cancers that are not otherwise classifiable because of 
contaminating normal epithelium. Nevertheless, the prognosis of this group is reported to be 
intermediate, with better survival than all but luminal A breast cancers. 
 
The identification of these molecular signatures has helped to understanding breast cancer and 
informed the search for novel therapies. However, this classification is a work in progress, 
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requiring refinement and standardization before it can be incorporated into clinical practice 
and decision making. Therefore, despite the progress and better understanding of the drivers 
of this disease, from a clinical management perspective, breast cancer remains divided into 3 
therapeutic categories: 
1. ER+ disease, which is targeted with antiendocrine strategies 
2. HER2+ disease, which is treated with HER2-targeted agents 
3. Triple negative breast cancer, which lacks validated targeted therapy options and is 
treated with traditional cytotoxic therapy 
 
1.4. Estrogen and estrogen receptor 
Estrogen is an important regulator in the development and progression of breast cancer and 
also in the development of normal breast. More than a century ago, Scottish surgeon George 
Beatson performed an oophrectomy and noted this procedure induced regression of breast 
cancer which was later proven to be due to a reduction in systemic estrogen levels (11). 
Estrogen mainly originates in the ovaries in pre-menopausal women, whereas in post 
menopausal women the main source is in the aromatization of androgens in adipose tissue. 
This accounts for the difference in therapeutic regimen between the two groups of women. 
Estrogen functions by activating two nuclear steroid receptors: ERα and ERβ. Both receptors 
bind estrogen and initiate gene transcription through ERE (estrogen response elements) in 
estrogen target tissues but have distinct functions and tissue distribution (12). In most breast 
carcinomas (~70%) ERα  is highly expressed which results in the increased rate of 
proliferation without differentiation or apoptosis. ERα  is exclusively epithelial (13, 14) 
whereas the distribution of ERβ  in breast cancer is exclusively nuclear but expressed in 
multiple cell types (stromal fibroblast, endothelial and immune infiltrating cells) its 
expression has also been shown to correlate with an increase in aggression of the tumor (15). 
ERβ expression has been reported to range from 26% to 94%, the lowest of which was in a 
Japanese study, this implicates that the expression could be related to ethnicity. When 
Caucasian cohorts of patients were compared, the range was less extensive at 74%-94% (14). 
The expression of ERβ  in the breast has been well described although its usual function, 
clinical value in carcinogenesis, and its relevance to the pathological diagnosis of breast 
cancer, is yet to be determined (14). Estrogen receptors that are not bound to ligand are 
inactive and usually sequestered in multi-meric protein complexes organized around the 
molecular chaperone heat shock protein 90 (HSP90). ER signaling pathways can be classed 
into 4 main mechanisms of action: Classical, ERE independent, ligand independent and non-
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genomic (Figure 4). Classically, the cytoplasmic ER translocates into the nucleus upon ligand 
binding. In the cytoplasm, the receptor dimerizes, transcription factors and co-activation 
proteins are recruited, and the target genes are then activated through an estrogen response 
element (ERE). Estrogen activates genes that are involved in survival and cell proliferation 
amongst other actions (16, 17). Estrogen bound ER interaction with Fos and Jun, which 
dimerize and become part of the activator protein-1 (AP-1) complex modulating gene 
expression. This ligand bound ER gene modulation can also occur with GC box bound 
specificity protein -1 (SP- 1) this is ERE independent modulation. ER can act independently 
of estrogen by being phosphorylated on multiple residues within the receptor after growth 
factor activation. The phosphorylation of  ER leads to the dimerization of the receptor, DNA 
binding and ultimately activation of transcription (18). Estrogen can also activate membrane 
bound ER and cause a rapid estrogen signaling response through non-genomic activation (19). 
The non-genomic simulation of the estrogen receptor is a rapid response to the ligand binding 
and its response in the cell is independent of the gene transcription. Estrogen receptors act 
through a complex interplay of signaling cascades; such as insulin-like growth factor 1 
receptor (IGF-1 R) (20), EGFR (21), G- proteins, Src, and PI3K. 
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Figure 4. A simplified view of the 4 mechanisms by which estrogen can exert its action upon a cell (roles and 
names of co-factors have been omitted). 1, Classical pathway: This is a genomic, ligand dependent mechanism; 
where estradiol (E2) bound dimers bind to the EREs in target promoter genes; this leads to an up regulation or 
down regulation of gene transcription and resulting in the estrogenic effects being seen in the cell. 2, ERE 
independent pathway: this is also a genomic, ligand dependent mechanism where estrogen bound ER dimers 
bind to alternative gene response elements such as AP-1 through Fos and Jun association and thus lead to gene 
transcription. 3, Ligand independent mechanism: this is a genomic ligand independent mechanism where the 
phosphorylation and subsequent activation of the ER, following growth factors and/or signalling molecules 
stimulation leads to target gene transcription. 4, the non-genomic ligand dependent mechanism; this is where the 
estradiol binds to a membrane associated receptor activating intracellular signalling generating rapid estrogenic 
effects in the cell.  
 
1.5.  Therapy for the different subtypes of breast cancer 
Development of new therapeutics for breast cancer has resulted in new agents directed against 
certain molecular targets such as c-met (22), HSP90 (23), or angiogenesis related targets such 
as VEGFR2 (24), signalling pathways such as mTOR (25) all of which could prove to aid in 
treatment of the heterogeneous disease and a more unique patient treatment regimen. 
Presently, the majority of these new therapeutic agents are not clinically available and most 
are at preliminary laboratory stage of investigation. 
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1.5.1. ER-positive breast cancer: Endocrine Therapy 
Patients with high levels of ER are treated with endocrine therapy (26). Endocrine therapy for 
breast cancer involves Selective ER Modulators (SERMS) which act as ER antagonists in 
breast tissue or aromatase inhibitors (AI) which work by inhibiting the action of the enzyme 
aromatase which converts androgens into estrogens (27). 
Targeting the ER is well established in the treatment of early and advanced ER
+
 breast cancer. 
Tamoxifen, a selective ER modulator, was approved in the late 1970 for the treatment of 
postmenopausal women with breast cancer. Later, its role in preventing disease recurrence 
was established, and tamoxifen was incorporated into adjuvant therapy, for all women with 
ER
+
 breast cancer (28). In the mid-1990, anastrozole was the first aromatase inhibitor (AI) 
developed for postmenopausal women with ER
+
. Other AIs, letrozole and exemestane, are 
applied in both the metastatic and adjuvant settings. The AIs have shown increased efficacy 
compared with tamoxifen, but their benefit is limited to postmenopausal women based on 
their mechanism of action, which causes a paradoxic estrogen surge in women with 
functioning ovaries. Fulvestrant, a selective ER downregulator, was subsequently developed 
for postmenopausal women with ER
+
 following antiestrogen therapy. In premenopausal 
women, tamoxifen remains the first antiendocrine strategy in both the adjuvant and metastatic 
setting. The role of ovarian suppression has been explored and in premenopausal women with 
metastatic breast cancer , the combination of tamoxifen with ovarian suppression improves 
survival (29). Despite these effective antiendocrine strategies, several patients develop 
treatment resistance. This may be caused by de novo resistance or acquired resistance shown 
by refractory disease following an initial period of response. Extensive efforts have been 
made to better elucidate mechanisms of resistance to identify potential therapeutic targets that 
may overcome this resistance. Signaling downstream of ER involves multiple pathways, 
including mitogen-activated protein kinase (MAPK), phosphatidylinositide 3-kinase 
(PI3K)/AKT/mammalian target of rapamycin (mTOR), epidermal growth factor receptor 
(EGFR), insulin like growth factor receptor (IGF-IR), fibroblast growth factor (FGF) receptor.  
Inibition of ER may cause up regulation of these alternative pathways, driving resistance to 
therapy (Figure 5). 
 
18 
 
 
Figure 5. Intracellular ER bound with their ligand estrogen, leads to cell survival and proliferation. Therapy with 
tamoxifen, AIs and fulvestrant blocks this signaling. However, there is a crosstalk between the ER pathway and 
other growth pathway as AKT, MAPK, EGFR, and activation of these pathways are implicated in resistance to 
antiendocrine therapy. 
 
 
Endocrine resistance in breast cancer cells is associated with increased activity of PI3K/AKT 
(30). There are significant interest in targeting mTOR, a downstream mediator of this 
pathway. Inibition of mTOR using inhibitors developed for transplant immunotherapy, 
restored sensitivity to endocrine therapy in breast cancer cells. The combination of everolimus 
(an mTOR inhibitor) and exemestane (an AI) improved progression-free survival (PFS).  
There is also interest in targeting PI3K, the upstream driver of the PIK3/AKT/mTOR 
pathway. PI3K is commonly mutated in breast cancer and activation of this pathway has been 
implicated in acquired and de novo resistance to endocrine therapy. There is a crosstalk 
between ER and PI3K/AKT pathways; however they also signal independently, suggesting 
that dual pathway targeting may be required to optimize outcomes. There are trial that are 
studying the role of PI3K inhibitor BKM120 with fulvestrant in women who have progressive 
ER
+
 metastasis breast cancer (MBC) folloving an AI (NCT01610284). An ongoing trial is 
studying fulvestrant with or without GDC0941, an alternative PI3K inhibitor in a similar 
population. The outcome of these studies will further inform the role of targeting this 
pathway. 
In addition to mTOR, over expression of the HER2 proto-oncogene has been clinically 
validated as a mediator of resistance to endocrine therapy. But this applies only to a small 
subgroup because only 10% of ER
+
 are also HER2
+
. HER2-driven resistance to antiendocrine 
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therapy is mediated via decreased ER level and increased ER phosphorylation, altered ER 
transcription, and activated downstream PI3K/AKT and MAPK pathways. Dual targeting of 
both ER and HER2 overcomes this resistance in preclinical models. Crosstalk between the 
HER2 and ER pathways is thought to drive endocrine therapy resistance. In ER
+
 HER2
-
 cell 
lines with acquired resistance, lapatinib, an oral tyrosine kinase inhibitor of HER2, was able 
to restore sensitivity (31). In a study, women with ER
+
 HER2
+
 and metastatic breast cancer, 
the combination of anastrozole (AI) and trastuzumab, a monoclonal antibody to HER2, 
improved response rate (RR) and progression free survival (PFS) (32). 
 
1.5.2. Anti EGFR therapy 
EGFR is a member of the HER family of receptors, along with HER2.  
Lapatinib is an oral small-molecule dual inhibitor of both EGFR (HER1) and HER2 kinases. 
Lapatinib exerts its antitumor effects by inducing growth arrest and or apoptosis, as well as by 
blocking downstream MAPK and AKT signaling pathways. Cetuximab is a monoclonal 
antibody that binds to the EGFR with high specificity blocking ligand-induced 
phosphorilation and activation of EGFR. 
In preclinical models, EGFR contributes to endocrine resistance; but clinical trials targeting 
this pathway have had only moderate success. For metastatic breast cancer (MBC)  ER
+
, the 
addition of gefitinib to anastrozole as first line therapy, improved PFS.   However, gefitinib 
monotherapy show a clinical benefit rate of 54% in tamoxifen resistant MBC (33). 
 
 
1.5.3. Anti HER2 positive therapy 
The HER2 protein is over expressed and/or its gene is amplified in approximately 20% of 
invasive breast cancers, and it is associated with more aggressive biology, increased risk for 
progression of disease, and decreased overall survival (OS). The HER2 receptor is composed 
of an extracellular ligand binding domain, a single transmembrane domain and an intracellular 
domain with tyrosine kinase activity. Advances in translational science have led to the 
development of several therapies that target HER2, including the monoclonal antibody 
trastuzumab. This antibody selectively binds to the external ligand-binding domain, 
downregulates the ligand-independent HER2 dimerization and growth factor signaling 
cascades downstream of HER2, including the PI3K/AKT/mTOR pathway, thereby 
suppressing HER2 activity. In 2001 was first shown that trastuzumab have clinical benefit for 
patients that are HER2 positive, amplified or overexpressed, in a study of randomized trial the 
addition of trastuzumab to chemotherapy was associated with higher overall RR and 
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improved PFS and OS, in patients with MBC. Another therapeutic strategy for suppression of 
HER2 activity, is represents by inhibition of the tyrosine kinase domain with low-molecular 
weight tyrosine kinase inhibitors (TKI). Examples include lapatinib, gefitinib, erlotinib; 
however, many tumors either exibit de novo resistance to anti-HER2 therapy or acquire 
resistance over time, leading to disease progression and shortened survival for patients.  More 
recently, novel agents with varying mechanisms of action have been described, and emerging 
data indicate that combinations of anti-her2 agents may overcome resistance (34).  
 
1.6. Triple negative breast cancer : TNBC 
Triple negative breast cancers represents the most problematic subtype with regard to 
effective management because there are no effective treatment targets. This type of cancer 
accounts for nearly 20% of all breast cancers. TNBC are tumors that do not express ER, PR, 
and HER2. TNBC is associated with younger age and more aggressive tumor type. In this 
subgroup the antiendocrine and anti-HER2 targeted therapies are ineffective, and traditional 
cytotoxic chemotherapy seems to be insufficient. Approximately 19.5% of triple negative 
patients carry BRCA mutations (35). Preclinical evidence suggests platinum-based therapy for 
TNBC and BRCA-1 associated malignancy is of benefit because it causes DNA cross-link 
strand breaks. In cells that lack homologous repair (ie, BRCA1 associated breast cancer), 
carboplatin or cisplatin have been hypothesized to have particular anticancer activity by 
leveraging the vulnerability of the cancer cell to DNA damage. In patients with triple negative 
breast cancers, the use of PARP inhibitors (polyadenosine diphosphate ADP-ribose 
polymerase) are novel strategy employed in clinical trials.  
 
 
1.7. Breast cancer in men 
Carcinoma of the male breast is a relative rare disease that accounts for less than 1% of all 
cases of cancer in men. The median age at diagnosis is 68 years compared with 63 years in 
women (36). The risk factors for breast cancer in men involve abnormalities in estrogen and 
androgen balance, which indicates that breast cancer in men, as in women, may be 
hormonally driven. An elevated risk has been seen in patients with undescended testes, 
congenital inguinal hernia, orchitis, testicular injury, infertility, and the Klinefelter syndrome, 
which is characterized by a 47, XXY karyotype, small testes, azospermia, and gynecomastia. 
Other possible risk factors that relate to hormonal levels include obesity, which causes 
increased peripheral aromatization of estrogens, and cirrhosis, which results in a 
hyperestrogenic state (37). Approximately 15% to 20% of male patients with breast cancer 
21 
 
have a positive family history (38). In women, the breast cancer susceptibility genes BRCA1 
and BRCA2 are thought to account for most hereditary breast cancers (40% to 70% risk for 
developing breast cancer). In men, BRCA1 does not appear to be associated with a 
significantly increased risk for breast cancer, however, men with BRCA2 mutations are 
predisposed to breast cancer. All of the histological subtypes of breast cancer that have been 
described in women, have also been reported in men. Approximately 90% of all breast tumors 
in men are invasive carcinomas; the remaining 10% are noninvasive. Almost all of the 
noninvasive cancers are ductal carcinoma in situ. Carcinomas of the male breast have a higher 
rate of hormone receptor positivity than do carcinomas of the female breast when matched for 
tumor stage, grade, and patient age. 81% of breast cancers in men are ER
+
, and 74% are PR
+
. 
In contrast to women, men do not have a higher incidence of estrogen receptor positive 
tumors with advancing age (39). As in women, lymph node status, tumor size, histological 
grade, and hormone receptor status have been shown to be significant prognostic factors in 
men with breast cancer.  
 
 
1.8. Classification of non coding RNAs 
Non-coding RNAs (ncRNAs) are RNA molecules that do not function by encoding for 
proteins. They are loosely grouped into two major classes based on their size: small ncRNAs 
less than 200 nucleotides (nt), and long ncRNAs (lncRNAs) longer than 200 nt. LncRNAs are 
mRNA-like transcripts ranging in length from 200 nt to ~  100 kilobases (kb) lacking 
significant open reading frames. Many identified lncRNAs are transcribed by RNA 
polymerase II (RNA pol II) and are polyadenylated. Although only a minority have been 
characterized in detail, lncRNAs participate in diverse biological processes through distinct 
mechanisms. LncRNAs have been implicated in chromosome dosage-compensation, 
imprinting, epigenetic regulation, cell cycle control, nuclear and cytoplasmic traffing, 
transcription, translation, splicing, cell differentiation and others (40). A lncRNA could act as 
a scaffold that keeps proteins together, or as a guide that helps recruit proteins to specific 
genomic DNA sequences. For instance, several well characterized lncRNAs, including AIR, 
HOTAIR, and XIST, interact with chromatin-remodeling complexes and target them to 
specific genes, thereby affecting the ability of these complexes to regulate gene transcription.  
Small ncRNAs, ranging from 20 to approximately 300 nt in size, include a broad range of 
known RNA species that are involved in the most basic cellular mechanisms, such as tRNA 
and rRNA which are essential for fundamental cellular functions, splicing RNAs (snRNAs) 
that regulates mRNA splicing, site specific RNA modification, telomere synthesis, 
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transcription, modulation of protein function and regulation of gene expression. In some 
cases, the molecular mechanisms are well understood, whereas in others they are completely 
unknown. Transfer RNAs (tRNAs) serve as key molecules to decode the genetic information 
stored in mRNAs by base pairing with cognate codons  on the mRNA and delivering amino 
acids to the translation machinery. However, recent research implied tRNAs also in signal 
transduction pathways responding to nutrient deprivation, regulation of apoptosis and in the 
retroviral life cycle. Small nucleolar RNAs (snoRNAs) are involved in ribosomal RNA 
(rRNA) processing and are responsible for the 2’O-methylation or pseudouridylation of 
rRNAs, snRNAs and tRNAs. Novel reports furthermore show that smaller processed forms of 
snoRNAs are able to act as miRNAs or regulate alternative splicing of the serotonin receptor 
2C. Small nuclear RNAs (snRNAs) are part of the spliceosome complex directing the 
accurate removal of intronic sequences of pre-mRNAs (41). 
However, the most extensively studied small RNAs in cancer are microRNAs (miRNAs).  
 
 
1.8.1. Introduction to miRNAs 
 
The first miRNA was discovered in 1993 by Victor Ambros and colleagues Rosalind Lee and 
Rhonda Feinbaum. They reported that the Caenorhabditis elegans gene lin-4 coded for a 
small antisense RNA complementary to a developmentally regulated protein-coding gene lin-
14. The second miRNA, let-7, was found 7 years later, also through forward genetics 
approaches in worms.  
After the initial discovery, microRNAs have undergone a long period of silence. It took 
indeed several more years to realize that these small RNA molecules are actually expressed in 
several organisms, including Homo sapiens, and are highly conserved across different species, 
highly specific for tissue and developmental stage. MicroRNAs  play crucial functions in the 
regulation of important processes, such as development, proliferation, differentiation, 
apoptosis, metabolism and stress response, as well as human diseases, such as diabetes, 
immune or neurodegenerative disorders, heart disease, vascular diseases, viral infection and 
cancer (42). In the last few years, microRNAs have indeed took their place in the complex 
circuitry of cell biology, revealing a key role as regulators of gene expression. To date, more 
than 1,500 miRNAs (www.mirbase.org) and over 8,000 long non-coding RNAs (lncRNAs) 
are known to be encoded by the human genome. It is estimated that more than 30% of the 
human genome is targeted by miRNA (43). Half of the known miRNAs are located inside or 
close to fragile sites and in minimal regions of loss of heterozygosity, minimal region of 
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amplifications, and common breakpoints associated with cancer, suggesting that microRNA 
abnormalities play a broad role in cancer development (44). For example, the miRNA cluster 
17-92 is located at 13q31, a region commonly amplified in lymphomas; miR-143 and miR-
145 are located at 5q33, which is frequently deleted in myelodysplastic syndromes; and a 
rearrangement of miR-125b-1, juxtaposed to the immunoglobulin heavy chain locus, was 
described in a patient with B cell acute lymphocytic leukemia. Several groups, including our 
own, have systematically analyzed miRNA expression in cancer samples and their 
corresponding normal tissues (45). In both hematological malignancies and solid tumors, 
including breast cancer, miRNA were discovered aberrantly express, creating a “signatures” 
that distinguish between tumoral and normal cells.  
 
 
1.8.2. Genomic organization of miRNAs 
 
MiRNAs are not randomly distributed throughout the genome. It was found early on that 
miRNAs can form polycistronic transcripts consisting of clearly defined clusters within the 
genome (46). It is often found that clusters were formed by local duplication of an existing 
miRNA locus. Nevertheless, there are also many cases of miRNA families with paralogues at 
different genomic locations, and also miRNA clusters containing a wide variety of miRNA 
families. These loci can be found in several different patterns of genomic organization (Figure 
6). MiRNA loci can be intergenic, encoded in monocystronic or polycistronic transcripts. 
They are also frequently found in the introns of protein-coding genes. In rare circumstances, 
miRNAs can also be found in the exons of protein coding genes (47), or be derived from other 
classes of non-coding RNAs. It is important to note that what we consider to be exonic 
miRNAs is dependent on our knowledge of precise gene splicing patterns. It has also been 
found that miRNAs can form a whole intron by themselves, thus bypassing the requirement of 
Drosha for their processing. Genomic miRNA clusters tend to be relatively small, rarely 
containing more than five or six distinct loci. Nevertheless there are exceptions. Human 
chromosome 14 contains the largest known cluster of miRNA loci that is conserved among 
many species, containing 37 miRNA loci, belonging to 6 distinct miRNA families. Other 
large clusters have been described, namely the cluster that is present on Human chromosome 
19, and is conserved in most other primates that have been sequenced to date. Repeat derived 
miRNAs can be located in locally duplicated clusters along the genome (e.g. miR-427 and 
miR-430) or be spread in an almost random fashion throughout the genome (e.g. miR-548). 
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Figure 6. Possible genomic organization of miRNA loci. In rare cases, miRNA loci can be contained inside an 
exon, or be the exclusive feature within an intron, which allows its maturation using the splicing machinery 
instead of requiring Drosha (miRTron). 
 
 
 
1.9.  Current Model of Mammalian miRNA Maturation and Processing 
MicroRNA genes represent approximately 1% of the genome of different species, and each of 
them has hundreds of different conserved or nonconserved targets: it has been estimated that 
approximately 30% of the genes are regulated by at least one microRNA. MiRNAs may be 
located either within the introns (mirtron) or exons of protein-coding genes (70%) or in 
intergenic areas (48) (30%). Mirtrons representing a subspecies of miRNAs, were firstly 
discovered in D. Melanogaster (49). Mirtrons constitute 5-10% of miRNA genes in 
invertebrates and vertebrates, they are expressed at much lower levels than typical canonical 
microRNA (50). Canonical miRNA are processed by the endoribonuclease Drosha; mirtrons 
are instead processed by the spliceosome.  MiRNAs are higly conserved, small, noncoding 
RNA molecules, 19-22 nucleotides in lengh, which control the expression of genes on the 
post-transcripional level. MicroRNAs are transcribed for the most part by RNA polymerase II 
as long primary transcripts, up to several kilobases, characterized by hairpin structures (pri-
microRNAs) 5’ capped, spliced and polyadenylated, and then processed into the nucleus by 
the enzyme RNAse III Drosha and its cofactor DGCR8 (DiGeorge syndrome critical region 
gene 8), into 70- to 100-nts long pre-microRNAs. These precursor molecules are exported 
through the nuclear pores by Exportin 5-mediated mechanism to the cytoplasm, where an 
additional step mediated by the RNAse III Dicer generates a dsRNA of approximately 22 nts, 
that consists of the leading-strand miRNA and its complementary miRNA sequence,  named 
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miR/miR*(miRNA star). This duplex RNA is unwound by a helicase into a single-stranded 
miRNA. The mature single stranded microRNA product is then incorporated in the complex 
known as microRNA-containing ribonucleoprotein complex (miRNP), miRgonaute, or 
microRNA-containing RNA-induced silencing complex (miRISC), whereas the other strand is 
likely subjected to degradation (Figure 7). However there are also reports of functional 
miRNA* sequences, especially under distinct cellular conditions and in different tissues. For 
example, in the case of miR-126/miR-126*, both miRNAs are stable and mediate 
characteristic functions (51).   
 
 
 
 
 
Figure 7 Biogenesis of miRNAs. miRNAs are transcribed as RNA precursor molecules (pri-miRNA), which are 
processed by Drosha and its cofactor DGCR8 into short hairpin structures (pre-miRNA). These are exported into 
the cytoplasm, where they are further processed into mature single-stranded miRNAs by the endonuclease Dicer. 
Those mature miRNAs are incorporated into the RISC complex and regulate posttranscriptional gene expression 
through various mechanisms 
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1.10. Molecular mechanisms of miR action 
 
The activity of mature miRs is dependent upon the recognition of a target sequence within 
mRNAs. For the most part, the mature 22-nt strand recognizes complementary sequences in 
the 3’ untranslated region (3’UTR) of target mRNAs, and are short and often imperfectly 
complementary.  
Typically, functional target sites consist of a 6-7 nt sequence complementary to the “seed 
sequence” of the miR, followed by an A residue, but may contain further regions of 
complementarities further upstream. These rules permit miR targets to be predicted from 
mRNA sequences; however such prediction algorithms are imperfectly specific and sensitive, 
and need to be experimentally validated in each case. Perfect miRNA:mRNA 
complementarity leads to cleavage of the mRNA by AGO2; this is the small interfering RNA 
(siRNA) pathway, which while important experimentally, is not thought to occur with 
endogenous mammalian miRs. Instead, the imperfect pairing with mRNA causes a down-
regulation of translation. The mechanism by which this occurs is still not clear; there is 
evidence supportive of models that translation is affected at initiation (52), or during 
elongation (53) (Fig. 8). A third possibility is that different mechanisms are used at different 
times, with the intriguing observation that in one system at least, the nature of the promoter 
driving mRNA synthesis can determine at which stage down-regulation occurs (54). 
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Figure 8.  Mechanisms of miR action. (A) A stereotypical miR: 
mRNA hybrid. (B) Modes of miR-mediated down-regulation of gene 
expression. 
 
 
 
 
 
 
1.11. MiRNA Classification  
 
The discovery of miRNAs caused a new surge of research in the field of molecular biology. 
To ensure the identification of novel miRNAs is properly regulated, in 2003, V. Ambros 
established universal guidelines for proper miRNA annotation (55). Briefly, legitimate 
miRNA identification must follow expression and biogenesis criteria, in which evidence is 
required for the expression of a distinct ~22 nt RNA transcript, together with a miRNA 
precursor that contains the miRNA sequence in one arm of the stem-loop structure. 
Additionally, phylogenetic conservation of the suspected miRNA as well as the predicted 
precursor must also exist, in addition to conservation of the 5’ terminus containing the seed 
region. Furthermore, when Dicer function is purposely disabled, evidence must support 
increased accumulation of the predicted precursor to ensure that the processing pathway of the 
miRNA involves Dicer. A single one of these conditions is insufficient on its own to annotate 
a novel miRNA, and evidence of both expression and biogenesis must be included (56).  
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Mature miRNAs are named using a “miR” prefix, followed by an identification number (ie. 
miR-31), however if only the miRNA precursor has been determined then the miRNA will be 
annotated using “mir.” Additionally, the gene encoding the miRNA uses the same prefix, 
although it is italicized (ie. mir-31) (56, 57). Letters preceding the “miR” prefix refer to the 
organism that the miRNA is found in (ie. hsa-miR-31 refers to Homo sapien or mmu-miR-31 
refers to Mus musculus). A letter occurring after the identification number refers to its relation 
to another miRNA, which may only differ from another by 1 or 2 nt (ie. miR-200a is related 
to miR-200b). The designation of “3p” or “5p” following the identification number refers to 
the arm from which the miRNA is contained in the pre-miRNA, while a “*” in the miRNA 
name refers to the passenger strand miRNA, which appears as a minor product in some cell 
types. However, the most recent version of miRBase (version 17.0) released in 2011 states 
that miR and miR* annotations will be changing to miR-3p and miR-5p, since accumulating 
evidence shows that the passenger strand may actually dominate over the supposed mature 
miRNA in some tissue or cell types (55). 
 
1.12. Experimental techniques for miRNA analysis 
The explosion of interest in miRNAs over the past few years necessitates effective tools for 
detecting their presence, quantification, and functional analysis. Isolation of miRNAs from 
specimens required modification of existing RNA extraction protocols, to take into account 
their tiny size and unique structure. Column based approaches were adapted to selectively 
capture and retain both the large and small RNA fractions e.g. using Qiagen RNeasy kits. Co 
purification methods have also been developed to isolate total RNA, inclusive of the small 
RNA fraction. MiRNA expression profiling has been facilitated by the advent of high-
throughput profiling techniques such as miRNA microarrays and bead-based miRNA 
profiling. These methods are far superior to existing low through-put techniques, such as 
Northern blotting and cloning. 
 
1.12.1. Microarray 
Microarray technology has also advanced to facilitate miRNA expression profiling. Labelling 
and probe design have improved to address the poor specificity initially observed when array 
technology could not distinguish between signals from premiRNA, pri-miR and mature 
miRNA sequences. Castoldi et al described a novel miRNA microarray platform using locked 
nucleic acid modified capture probes (58, 59). Locked nucleic acid modification improved 
probe thermostability and increased specificity, thus enabling miRNAs with single nucleotide 
differences to be discriminated—an important consideration as sequence-related family 
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members may be involved in different physiologic functions (60). An alternative high-
throughput miRNA profiling technique is the bead-based flow cytometric approach developed 
by Lu et al (61), a method which offers high specificity for closely related miRNAs because 
hybridisation occurs in solution. The high throughput capability of array based platforms 
make them an attractive option for miRNA studies compared with lower throughput 
techniques such as Northern blotting and cloning, which remain essential for the validation of 
microarray data. 
 
1.12.2. Next generation sequencing techniques 
One of the limitations of microarray expression profiling is the requirement of prior sequence 
information to be used for probe design. Until recently, this sequence information has been 
limited mostly to that found in public databases (e.g. miRBase). These data have been 
gathered mainly through a combination of bioinformatics, and extensive cloning experiments. 
In contrast, deep sequencing is not dependent on any prior sequence information. Instead it 
provides unbiased information about all RNA species in a given sample, thus allowing for 
discovery of novel miRNAs or other types of small RNAs that have eluded previous cloning 
and standard sequencing efforts. Next generation sequencing utilizes massively parallel 
sequencing, generating millions of small RNA sequence reads from a sample (62). This 
provides an excellent tool for those studying species where limited sequence information is 
currently available. Additionally, new sequence information generated using these techniques 
can be used to design improved microarray platforms for future large scale expression studies 
(63). Currently available deep sequencing technologies include the Roche 454 and Illumina’s 
Solexa platforms. Roche 454’s platform utilizes emulsion PCR for template amplification, 
and pyrosequencing technology on a high well-density picotiter plate. Illumina’s Solexa 
platform uses bridge amplification on glass surface for template preparation and reverse 
terminator technology for sequencing. Both platforms provide high throughput and high 
quality sequencing production at low cost. In conjunction with the evolution of next 
generation sequencing technologies, which generate massive amounts of data, bioinformatic 
tools have had to evolve in concert. Several bioinformatics analysis programmes have been 
developed specifically to interpret and interrogate deep sequencing data. Examples include 
miRDeep, deepBase, miRExpress, and miRanalyzer. As these highly sophisticated techniques 
continue to develop, the extent and significance of miRNA regulation of gene expression will 
become even more evident. 
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1.12.4. Real time Quantitative PCR 
Quantitative real-time PCR (RQ-PCR) methodologies are considered the gold standard for 
quantification of nucleic acid levels (64) and have been widely applied to miRNA 
investigations. This technique is based on the quantitative relationship between the amount of 
starting target sample and the amount of PCR product at any given cycle number. The RQ-
PCR process involves a reverse transcription (RT) reaction to convert isolated RNA into 
complementary DNA (cDNA), amplification of the cDNA using PCR, and quantification of 
the amplicons in real-time. Whilst the steps involved in RQ-PCR have largely remained 
constant since its conception (65), the technology has evolved to become increasingly 
sensitive, specific and versatile. The short length of mature miRNAs posed difficulties 
initially, but with the design of effective primers and probes with adequate specificity, this 
was overcome. Random primers and poly-T oligonucleotide primers are not suitable for RT of 
miRNA given their short length and the absence of a polyadenylated 3’ tail. To overcome this, 
the extracted small RNA may be polyadenylated using a poly (A) polymerase followed by a 
RT reaction using a poly-T oligonucleotide primer. Alternatively, a gene-specific, stem-loop 
RT primer may be used (66). When compared to linear RT primers, the stem-loop RT primers 
are far superior in discriminating between miRNA sequences that differ slightly and are at 
least 100 times better at discriminating between the mature miRNA and its longer precursor. 
The stem-loop creates steric hindrance that prevents priming of the precursor miRNA. To 
date, the most successful approach in terms of specificity and sensitivity is a two-step 
approach using looped miRNA-specific reverse transcription primers and TaqMan probes 
from Applied Biosystems, (67). The stem-loop structure is specific to the 3’end of the mature 
miRNA. It extends the short mature miRNA and adds a universal 3’ priming site for real-time 
PCR. To correct for variables such as the amount of starting template and enzymatic 
efficiencies, RQ-PCR data is routinely normalized using endogenous control genes (‘house-
keeping genes’) which are stably expressed across a sample set. The appropriate choice of 
endogenous control is critical to ensure validity and accuracy of the results generated. 
Evidence exists to support particular miRNAs as appropriate normalizers for given datasets, 
depending on the tissue of origin. The many advantages of RQ-PCR in miRNA analysis 
include its efficiency, relatively low cost, low starting miRNA requirement, and the fact that 
both high and low abundance miRNAs can be detected. It is therefore particularly useful for 
validating the data obtained from miRNA microarray expression profiling. 
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1.13. MicroRNAs in Tumorigenesis  
1.13.1. Deregulation of miRNAs in cancer 
Since miRNAs participate in a vast array of normal functions, it seems logical that they would 
also be associated with abnormalities in disease states. Indeed, investigations based on this 
idea have revealed that alterations in miRNA genes have a significant involvement in cancer 
initiation and progression (68). MiRNAs expression is influenced by genomic abnormalities 
such as chromosomal amplifications or deletions, mutations, and rearrangements, which cause 
aberrant gene expression when compared to normal tissues. Calin et al. (2004) found that over 
50% of miRNAs are over-represented at fragile chromosomal regions prone to breakage or 
rearrangement, and are frequently altered in cancer. For example, two known tumour 
suppressor miRNAs that are clustered together, miR-15a and miR-16-1, are down-regulated in 
over 70% of human chronic lymphocytic leukemia (CLL) and their genes are situated at the 
13q14.3 loci, which is the region of deletion in human CLL. Abnormal miRNA expression is 
also caused by impairments of the miRNA processing machinery (69). Drosha up-regulation 
is apparent in approximately half of all cases of cervical squamous cell carcinoma (SCC), 
likely caused by an amplification mutation at chromosome 5p where the Drosha gene is 
located (70, 71). Additionally, Melo et al. (2009) found that mutations in TRPB led to Dicer 
destabilization in colorectal and endometrial cell lines, resulting in the global downregulation 
of miRNAs. This widespread miRNA downregulation has also been determined in other 
studies. Lu et al. (2005) did a systematic analysis on 217 different miRNAs in various 
tumours samples such as brain, breast, lung, colon, stomach, pancreas, kidney, and found that 
129 of them were downregulated in the tumours compared to normal tissues. Other miRNA 
profiling studies such as that performed by Volinia et al. (2006), which looked at 
characterization of six different tumour types (prostate, lung, breast, colon, pancreas, and 
stomach) have revealed that an abundance of miRNAs are both upregulated and 
downregulated in cancer cells compared to normal tissue (68). Moreover, many studies have 
been performed such as that by Liu et al. (2004) on human and mouse RNA profiling, which 
have revealed a specific pattern of miRNA expression in numerous tumour types. For 
example, Volinia et al. (2006) found that miR-21 was over-expressed in all six tumors types 
analyzed, while miR-191 was expressed in five. 
 
1.14. MiRNAs as tumor suppressor 
 
A miRNA, like a protein coding-gene, can act as a tumor suppressor when its function loss 
can initiate or contribute to the malignant transformation of a normal cell. The loss of function 
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of a miRNA can be attributed to several mechanism. For example to genomic deletion, 
mutation, epigenetic silencing and miRNA processing alteration. The family of let-7 (let-
7a,b,c,d) of miRNAs is down regulated  in many tumors including breast cancer (72). 
Many members of the let-7 family are located in fragile genomic areas associated with lung, 
breast and cervical cancer. Functionally, let-7 family members inhibit the mRNA of well-
characterized oncogenes, such as the RAS family, HMGA2 and c-myc, and induce apoptosis 
and cell cycle arrest when overexpressed in lung and colon cancer and in Burkitt lymphoma 
cell lines.  
MiR- 29 family members have been shown to be downregulated in CLL, lung cancer, 
invasive breast cancer, AML, and cholangiocarcinoma. The enforced expression of miR-29b 
induced apoptosis in cholangiocarcinoma and lung cancer cell lines and reduced 
tumorigenicity in a xenograft model of lung cancer (73). The tumor suppressor effects of the 
miR-29 family can be explained in part by the direct targeting of the antiapoptotic protein 
MCL-1 and the oncogene TCL-1.  
 
1.15. MiRNAs as oncogenes 
The amplification or over-expression of miRNAs which target tumour suppressors can lead to 
significant down-regulation of these tumour suppressors, or of genes involved in cell 
differentiation. This may incite uncontrolled proliferation, loss of apoptotic activity, promote 
angiogenesis and/or invasion, thus contributing to tumour formation. In this way, miRNAs 
can act as oncogenes. The list of miRNAs that function as oncogenes is short, but the 
evidence of their role is strong. One such oncomiR is miR-21. This miRNA is up-regulated in 
a variety of malignancies, including AML, CLL, cancers of the pancreas, prostate, stomach, 
colon, lung, breast and liver. Over-expression of miR-21 in glioma blocks apoptosis (74) 
whereas silencing its expression inhibits cell growth and increases apoptotic cell death by  
targeting genes such as PTEN, PDCD4 (programmed cell death 4), or TPM1 (tropomyosin 1). 
The polycistronic miR-17/92 cluster represents another miRNA with oncogenic function. 
Over-expression of the seven miRNAs in this cluster (miR-17- 5p, miR-17-3p, miR-18a, 
miR-19a, miR-20a, miR-19b, and miR-92–1) have been associated with a variety of 
malignancies (colon, lymphoma, breast, lung, pancreas, prostate and stomach. The 
mechanism by which this cluster acts is likely to be due to suppression of PTEN, a tumour 
suppressor gene and negative regulator of the highly oncogenic prosurvival PI3K/AKT 
signalling pathway. 
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MicroRNA Expression targets Role Function 
miR-15a 
miR-16-1 
downregulated in CLL Bcl-2, Wt-1 induce apoptosis and 
decrease 
tumorigenicity 
Tumor suppressor 
let-7 (a,b,c,d) downregulated in lung and 
breast 
cancer 
RAS, c-myc, 
HMGA2 
induce apoptosis Tumor suppressor 
miR-21 upregulated in breast, colon, 
pancreas, lung, prostate, 
liver, and 
stomach cancer; AML; 
CLL;  glioblastoma 
PTEN, 
PDCD4, 
TPM1, TP53 
induces apoptosis and 
decreases 
tumorigenicity 
Oncogene 
miR-29 
(a,-b,-c) 
downregulated in CLL, 
AMLa, lung,  breast 
cancers, 
cholangiocarcinoma 
TCL-1, MCL1, 
DNMT3s 
induce apoptosis and 
decrease 
tumorigenicity 
Tumor suppressor 
miR-17∼92 
cluster 
upregulated in lymphomas 
and in 
breast, lung, colon, 
stomach, and 
pancreas cancers 
PTEN, PI3K/AKT transgenic miR-17-92 
develop 
lymphoproliferative 
disorder 
Oncogene 
 
Table 1. Examples of miRNAs as oncogenic or tumor suppressor functions in cancer 
 
1.16. Therapeutic approaches of miRNAs 
 
There are two approaches to developing miRNA-based therapies: antagonists and mimics, 
depending on miRNA function and its status in the diseased tissue. MicroRNA antagonists are 
generated to inhibit miRNAs that acquire a gain of function in human disease.  MiRNA 
antagonists are conceptually similar to other inhibitory approaches, such as siRNAs and 
small-molecule inhibitors. The most common strategy to ablate miRNA function is achieved 
by single-stranded oligonucleotides with miRNA complementary sequences. The backbones 
of these are chemically modified to increase the affinity toward the endogenous miRNA and 
to sequester it in a configuration that is unable to be processed by RISC. Therefore, miRNA 
inhibition occurs upstream of RISC and presumably independently of cellular cofactors. 
Examples of miRNA antagonists are: anti-miR oligonucleotides (AMOs), antagomiRs, locked 
nucleic acids (LNA), and miRNA sponges. AMOs are single-stranded molecules that form 
direct complementarily and thus inhibit specific miRNA (75). 
AntagomiRs are single-stranded molecules that form complementarily to miRNAs but may 
also be modified with a cholesterol conjugated 2’-O-methyl in order to maintain stability 
while minimizing degradation (75). LNA have a methylene bridge that functionally locks 
ribose conformation. This change results in increased binding affinity and stability (75). 
MiRNA sponges represent a newly identified approach to miRNA. Sponges function by using 
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multiple complementary 3’UTR mRNA sites for a specific miRNA. Sponges competitively 
bind to miRNA, thus interfering with normal targeting of miRNA (76). There are several 
advantages to miRNA sponges, including the ability to target and inhibit a family of miRNAs 
as opposed to single miRNA targeting with antisense oligonucleotides.  
Several in vitro and in vivo mice studies have used AMOs against oncogenic miRNAs to 
induce cancer cell death and inhibit tumor proliferation, migration and invasion. For example, 
inhibition of miR-17-5 and miR-20a, belonging to the miR-17-92 miRNA cluster (which is 
over-expressed in lung cancer) using AMOs resulted in the induction of apoptosis in lung 
cancer cells (77).  
The only miRNA-based treatment tested in people is anti-miR-122 for the treatment of 
infection with hepatitis C virus (HCV). MiR-122 is an essential miRNA for HCV replication 
and is predominantly in the liver. In 2010, data from a drug trial of an intravenously delivered 
LNA to remove miR-122 and stop infection in chimpanzees was reported. No resistance or 
side-effects were noted in the treated animals (78). These results led to the first clinical trials 
of miRNA based treatments in people. A phase trial in healthy volunteers established that 
anti-miR-122 is safe and identified no dose-limiting toxicities. 
In contrast, miRNA mimics are used to restore miRNAs that show a loss of function. This 
approach, also known as miRNA replacement therapy, has attracted much interest as it 
provides a new opportunity to therapeutically exploit tumor suppressors. MiRNAs mimics, 
unlike proteins, are smaller and are able to enter cytoplasm of target cells using technologies 
that are also used for siRNAs. MiRNA mimics act downstream of RISC and require 
enzymatic functions of cellular RISC to be catalytically active. To date, few tumor suppressor 
miRNAs have been discovered for which miRNA replacement therapy has been demonstrated 
in pre-clinical animal models of cancer. 
The main example of miRNA replacement is exemplified by let-7. In lung cancer cells, let-7 
is expressed at reduced levels relative to normal lung cells. Studies using cultured lung cancer 
cells, as well as mouse models of lung cancer demonstrated that the re-introduction of let-7 
mimics blocks the proliferation of cancer cells and reduces growth of lung tumors in the 
animal (79).  
This preliminary results, are highly encouraging towards translating into human cancer 
therapy, and  indicate that miRNA based-treatment will become a central feature of cancer 
treatment and management. 
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2. Materials and methods 
 
2.1. Cell culture 
 
The human breast cancer-derived cell lines used in our experiments (Table S1 in 
supplementary) are: of adenocarcinoma origin: MCF-7, MDA-MB-231, MDA-MB-468, 
MDA-MB-361, SKBR3; of ductal carcinoma origin: T47D, BT474, ZR75.1; of metastatic 
origin: MDA-MB-453; of not clarified breast cancer origin: HBL-100; and the breast non-
tumor cell lines are:  of normal epithelium of breast origin: 184A1, MCF10A. All cell lines 
were purchased from the American Type Culture Collection (ATCC, Rockville, MD). Cells 
were grown as monolayers in DMEM (MCF-7, MDA-MB-231, MDA-MB-468, MDA.MB-
361, T47D, ZR75.1, HBL100, BT474), in DMEM-F12 (1:1 vol/vols) (184A1, MCF10A), and 
in McCoy's (SKBR3) (LONZA, Verviers, Belgium), supplemented with 10% of fetal bovine 
serum (FBS, LONZA) or 10% of horse serum (HS, LONZA) for MCF10A and 184A1, 
10µg/ml penicillin-streptomycin (Invitrogen, Carlsbad, CA), and 4mmol/L glutamine 
(Invitrogen). 184A1 and MCF10A were additionally supplemented with 10µg/ml bovine 
insulin, 100ng/ml cholera toxin, 0.5µg/ml hydrocortisone, 20ng/ml recombinant human 
epidermal growth factor (all from SIGMA, St. Louis, MO). Cells were maintained in a 5% 
CO2 atmosphere at 37°C. Subconfluent cells were counted daily and cell morphology was 
evaluated using an inverted phase-contrast microscope (Nikon, Melville, NY). Serum-starved 
cells were obtained by culturing the different cell lines for 72h or 96h in the presence of 0.1% 
fetal bovine serum. 
 
 
2.2. Analysis of mutation in breast cancer cell lines 
 
To evaluate which mutations were present in cell lines, DNA was extracted from 10 cell lines 
(ZR75.1, MCF7, HBL100, MDA-MB-361, 184A1, MCF10A, MDA-MB-453, SKBR3, 
MDA-MB-231, MDA-MB-468, T47D), according to the manufacturer’s protocol (DNA 
Extraction Kit, QUIAGEN). DNA samples was used to prepare a library using Ion Ampliseq 
Library kit v.2 (Life Technologies). The sequencing  was performed using Ion PGM 200 
Sequencing KIT  (Ion Chip 314 v.2) with the instrumentation Ion Torrent PGM, the chip 
contained the genes that are mutated in most breast cancer. These genes are reported in the 
Table S2 (in supplementary). 
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2.3. MicroRNA microarrays 
The miRNA oligo probes are 40 nt long, designed on the sense strand of the miRNA hairpin 
structure to cover both arms for the detection of mature and precursor miRNA. The oligo 
probes, modified with a  5’ amine C6 linker (which covalently binds probes onto the chemical 
matrix of the slide surface by the amine group and increases the accessibility of probes for 
target hybridization), are printed onto polymer-coated CodeLink-activated slides purchased 
from GE Healthcare (PN 300011). 
A quantity of 2.5µg of total RNA samples, extracted from the following cell lines: MCF7, 
T47D, BT-474, MCF10A, MDA-MB-231, SKBR3, MDA-MB-468, MDA-MB453, was 
directly reverse-transcribed with biotin-labeled random octomer primer to obtain labeled 
target cDNA, ready to be hybridized on the miRNA microarray chips. After hybridization of 
the biotin-labeled target cDNA with the probes on the array slides, the biotinylated 
target/probe complexes are stained by affinity binding of Streptavidin-Alexa 647 conjugate to 
the two biotin molecules present for each target cDNA. This allows an eightfold linear signal 
amplification (there are two biotin molecules per cDNA target and four Alexa 647 
fluorophores per streptavidin) with a substantial and reliable increase in sensitivity. Signal 
detection is obtained by laser excitation of the microarray, to allow the measurement of signal 
intensity. 
  
2.4. Transient miRNA Transfection 
In the transient transfection miRNA experiments we used synthetic Ambion® Pre-miR™ 
miRNA Precursor Molecules. This molecules are small, chemically modified double-stranded 
RNA molecules designed to mimic endogenous mature miRNAs, optimized to interact with 
the RNA-induced silencing-like complex responsible for miRNA activity. Pre-miR miRNA 
Precursors are not hairpin constructs and they are different from endogenous pre-miRNAs.  
All the breast cancer cell lines and breast non-tumor cell lines above mentioned, were 
transfected with either one of 38 miR (miR-21, miR-26b, miR-28-5p, miR-33b, miR-99a, 
miR-126, miR-126*, miR-130b, miR-138, miR-142-5p, miR-143, miR-181a, miR-202, miR-
203, miR-206, miR-210, miR-218, miR-222, miR-145, miR-301a, miR-302a, miR-320c, 
miR-326, miR-484, let7d*, miR-93, miR-103, miR-1307, miR-148, miR-328, miR-874, miR-
151, miR-10a, miR-25, miR-30a, miR-615, miR-27a, miR-9). A double-stranded non-
targeting control sequence was used as a negative control for the pre-miRs. All sequences 
were obtained from Ambion (Life Technologies, Austin, TX, USA). Negative controls and 
pre-miRs were used at a final concentration of 30 or 100 nM. For the experiments of 
proliferation using MTS assay, cells were seeded and transfected in the same moment, in 96 
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well in 0.1% FBS medium for 72h to 96h. Indeed, for the experiments of wound healing, 
invasion and proliferation with the xCELLigence RTCA System, cells were seeded on the day 
before transfection in 10% FBS medium in 12 well plate  to approximately 80% confluence; 
the day after transfected in 0.1% FBS medium using siPORT™ NeoFX™ Transfection Agent 
(Invitrogen, Life Technologies, Burlington, ON) and Opti-MEM media (Invitrogen) 
according to the SiPort protocol. Cells were incubated at 37°C and 5% CO2 for a range of 48 
to 96h. A GFP expression vector was used to assess the performance of various transfection 
protocols. 
 
2.5. Proliferation assay 
2.5.1. MTS assay 
The analysis of cell viability was carried out by performing a colorimetric assay using the  
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) CellTiter 96® AQueous Reagent Powder (PROMEGA, Madison, USA) and 
PMS (phenazine methosulfate) (SIGMA), both powder resuspended in phosphate buffered 
saline in a ratio 20:1. IN The live cells, the mitochondrial enzyme succinate dehydrogenase, 
metabolizes the MTS in purple formazan directly soluble in the culture medium. The 
formazan  has an absorbance maximum at 490nM. The value of absorbance is directly 
proportional to the number of living cells. For all breast cancer-derived cell lines, 6 x 10
3
 cells 
were seeded, and for normal ephitelium breast cell lines (MCF10A and 184A1), 12 x 10
3
 cells 
were seeded, into microplates tissue culture 96 wells, flat bottom, in a final volume of 100µl 
culture medium with 0.1% FBS per well for 72h and/or 96h incubation at 37°C and 5% CO2. 
Fifty micro liters of the mix MTS and PMS (final concentration 0.5mg/ml) were then added to 
each well and the microplates were further incubated for 1-4h at 37°C and 5% CO2. The 
absorbance (OD) of the samples was read with an SUNRISE
TM
 ELISA reader operating at 
492 nm (Tecan, Mannedorf, CH). All miRNAs have been transfected in quadruplicate and the 
experiment was repeated from 3 to 5 folds. As negative control a scramble miRNA was used. 
The blank, consisting of the medium and of siPort agent, was subtracted from each OD 
values. 
 
2.5.2. Analysis of data 
For the analysis of the experiments, once obtained the mean of the quadruplicates samples for 
each miRNA, we calculated the ratio between the value of each miRNA and the median of  all 
the samples. This procedure was repeated for all the experiment performed,  generating 
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several mean/median ratios. To obtain a value representative for all the experiments 
performed with one miRNA, we evaluated the median of all the mean/median ratios obtained 
(miRNA median). We evaluate also a cumulative median, which was the median of all the 
miRNA medians obtained for all the miRNA tested. We evaluated also, for every mirNA 
median,  the absolute deviation  from the cumulative median, utilizing the MAD (median 
absolute deviation) equation. We defined significant all the miRNA medians that we greater 
(or smaller) than the cumulative median plus (or minus) 2 MADs. The experiments on 
different cell lines were plotted as log2 of miRNA median. In addition, to better compare the 
miRNA effects on cell lines, we summarized all the results in tables, showing in red the 
miRNA median exceeding the cumulative median plus 2 MAD, and in green the miRNA 
median lowest than the cumulative median minus 2 MAD. 
 
2.5.3. Real-time cell proliferation assay  
Cell proliferation was determined by means of the xCELLigence RTCA System (Real-Time 
Cell Analyzer System, Roche Applied Science, Mannheim, Germany), developed to monitor 
cell events in real time, without incorporation of dyes, by measuring electrical impedance 
created by cells (80). RTCA station was placed inside the incubator at 37°C and 5% CO2. 
Cells were seeded in a E-Plate 96 microtitre plate device, as suggested by manufacter's 
specification. Briefly, background measurements were taken by adding 100µl of culture 
medium to the wells of the E-Plate 96. Subsequently, RTCA Software version 1.2 was used to 
calibrate the plates. A volume of 100 µl of cell suspension, at a concentration of  5000 cells 
⁄well, was then added to wells of the E-Plate 96 and allowed to settle at the bottom of wells, at 
room temperature for 30 min, before placing the E-Plate 96 on the RTCA Station. Each 
condition was performed in quadruplicate with a programmed signal detection every 15 min 
for a total of 96 h. Impedance values were converted into a dimensionless parameter termed 
cell index (CI). 
 
2.5.4. Real-time cell invasion assay 
Experiments for determining cell invasion were carried out using the xCELLigence RTCA 
system, according to the instructions of the supplier. Briefly, cell invasion was assessed using 
specially designed 16-well plates, CIM-plate 16, with 8 mm pores with the micro-electrodes 
located on the underside of the membrane of the upper chamber. The upper side of the 
membranes was covered with a layer of Matrigel. The Matrigel (BD Biosciences) was diluted 
1:20 with ice-cold serum-free medium. Preparation of a Matrigel layer on the CIM-Plate 16 
upper chamber membranes was carried out by adding 50 µl of the dilution followed by 
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immediate? removal of 30 µl, leaving a total of 20 µl Matrigel dilution. The coated 
membranes in the upper chambers were then incubated at 37 °C for at least 4h to ensure 
homogeneous gelification. The wells of the bottom chamber were then filled with 160 µl of 
10% serum containing medium and the top and bottom portions of the CIM-16 plates were 
assembled together. The assembled CIM-16 plate was allowed to equilibrate for 1h at 37 °C, 
5% CO2 after the addition of 50 μL of serum-free containing medium to the top chamber 
wells. Subsequently, 4×10
4
 cells⁄well were seeded onto the top chambers of CIM-16 plates 
and placed into the xCELLigence system for data collection every 15 min for a period of 24 h. 
Each condition was performed in quadruplicate with a programmed signal detection every 15 
min for a total of 24h. Impedance values were converted into a dimensionless parameter 
termed cell index (CI). 
 
2.6. Scratch wound healing assay  
For to test the effects of selected miRNAs on cell migration and cell proliferation, two  key 
process in the development and progression of cancer, we have used the scratch wound 
healing assay. This method is widely used because it is simple and inexpensive. The basic 
principle of the assay consist in creating a “wound gap” in a cell monolayer by scratch, 
followed by monitoring the “healing” of this gap by cell migrating and growth towards the 
centre of the gap, hereby filling up the “gap”. Factors that alter the motility and/or growth of 
the cell can lead to increased or decreased rate of “healing” of the gap.  
After the experiments of transfection and MTS assay, we have selected the miRNAs that gave 
the greater effect in a largest number of lines and analyzed  their effect on migration. This 
miRNA are: miR-138, miR-130b, miR-21, miR-210, miR-26b, miR-148, miR-1307, miR-99, 
miR-222, miR-126. We performed the wound healing assay on T47D, cells form MDA-MB-
468, SKBR3, MDA-MB-453, MCF7, MDA-MB-231, MCF10A, ZR751. Cell lines were 
seeded into 12 well plates in complete medium (10% FBS), then when they reached 80% of 
confluence, medium was removed and substituted with  medium containing 0.1% FBS and 
the complex of transfection plus the selected miRNA or negative control (miRNA scramble) 
at the concentration of 100 nm. Samples were in quadruplicate. Incubation was performed for 
48h. Then, using a 200 μl pipette tip, we performed a gently and slowly a straight vertical 
scratch. After scratching, we carefully washed the wells once with PBS to remove the 
detached cells; after that we replaced with fresh 0.1% FBS medium. For each well, we took 
three images with an inverted phase-contrast microscope at time T0, T24, T48h. By Image J 
software, we have measured the area of the scratch and the variation percent of the area 
during time.  
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2.7. Class comparison 
We analyzed gene expression data of every breast cancer cell line treated by six miRNAs ( 
hsa-miR-130b, -145, -210, -21, -126, -26b). First, we performed a class comparison analysis 
blocked by cell line type ( p-value < 0.05 ) to obtain the list of genes down-regulated and up-
regulated by the specific miRNA transfected versus the scramble vector.  Second, we 
performed a Spearman Correlation analysis ( p-value < 0.05 ) on the expression dataset 
obtained by the integration profiles of miRNA and RNA sequencing data of more than 500 
TCGA breast tumor samples . We found the positively and negatively genes correlated to the 
expression of a specific miRNA, that we have transfected in breast cancer cell lines. 
Therefore, we made an intersection of the two list of genes down-regulated, then we applied 
the same process for the up-regulated genes.   Finally, we had a list of the genes that were 
down-regulated  in vitro and in vivo (patients) that can be possible targets of each miRNAs 
selected. Fisher's two-sided exact tests were used to compare categorical and continuous 
variables between two groups. 
 
2.8. Total RNA isolation 
Total RNA was extracted using TRIzol reagent (Invitrogen Life Technologies), according to 
the manufacturer’s protocol. The adherent cells were lysed directly in 6-well plates with 1 ml 
of TRIzol. The samples were incubated for 5 min at room temperature to permit a complete 
dissociation of the nucleoprotein complex. 1ml lysate was transferred to a fresh tube, where 
0.2 ml chloroform was added, vortexed thoroughly and incubated for 10 min at room 
temperature, for phase separation. The samples were centrifuged at 12000g and 4°C for 15 
min, which led to the separation of the mixture into three phases (upper colourless aqueous 
RNA phase, middle DNA phase and lower red protein phase). The upper layer was carefully 
removed and transferred to a new tube, and 0.5 ml isopropanol was added and then mixed 
well. The mixture was allowed to stand at room temperature for 10 min, and then centrifuged 
at 12000g and 4°C for 20 min. The supernatant was removed and the RNA pellet was washed 
two times with ice-cold 75% ethanol and then centrifuged at 7500g for 5 min at 4°C. All 
leftover ethanol was completely discarded, RNA pellets were dried (not completely) for 5 min 
in the heat block at 65°C, then dissolved in RNAase-free water and measured in a 
spectrophotometer to determine the concentration and purity of RNA. 2 μl sample was diluted 
in 98 μl of DEPC-water and 50 μl of dilution was transferred to a spectrophotometer tube then 
measured. The A260/A280 absorbance was  above 1.7. Some samples were measured using a 
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Nanodrop spectrophotometer where only 2 μl was added directly to the machine without the 
need to dilute it; a RNAase free-water was used as blank.  
 
 
2.8.1. Quantification of RNA 
The concentration of RNA (ng/μl) for each sample was also measured using the NanoDrop 
1000 Specrophotometer (Thermo Scientific, Wilmington, DE, USA). RNA purity was 
measured with the A260/A280 absorbance ratio on the NanoDrop with acceptable RNA 
purity ranging from 1.9 to 2.1.  
 
2.9. Statistical analysis  
Data are presented as the mean ± standard error of mean  All experiments were done in 
quadruplicate and repeated. The Student t-test was used to assess the significance of 
independent experiments of  wound healing The criterion p < 0.05 was used to determine 
statistical significance. 
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Rationale  
Breast cancer is one of the major health problems worldwide and it is the second cause of 
cancer-related in women. Patients often develop resistance to the current therapies. For this 
reason, the identification of new specific clinical molecular marker and pharmacologic targets 
in cancer research is an ongoing challenge. Over the last years, microRNAs have become one 
of the main subjects of study in the area of cancer genomics. By regulating the expression of 
target genes, microRNAs can have a tumor suppressor or oncogenic role. Therefore, 
microRNAs are related to cancer process, including initiation, progression, growth, apoptosis, 
invasion and metastasis. A panel of 38 candidate miRNAs was chosen to investigate their 
effect on viability in 10 different cell lines of breast cancer origin, from the line more 
aggressive to the line minus aggressive, and 2 cell lines of breast normal epithelium. These 
miRNAs were chosen for two reasons. Firstly, a previous study on a microRNA microarray 
experiment, conducted by Volinia et al. (81) on different solid tumors and normal tissues, 
identified several microRNA which were differentially expressed in solid tumor, comprised 
breast cancer, compared to normal tissues. Secondly, several published reports also linked the 
miRNAs in this panel to breast cancer. Aim of the present study was to evaluate the effect of 
the selected miRNAs on several in vitro parameters, like as cell viability, proliferation, 
invasion and their capacity of wound healing. In addition, we have analyzed the influence of 
some miRNAs which resulted to in vitro influence cell growth, on  transcription both in cell  
lines and patients. 
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3. Results and discussion 
 
3.1. Genomic characterization of cell lines 
 
As first step, we characterized genomic integrity of the lines selected for this study, in order 
assess if they actually correspond to literature reports. We used Ion PGM 200 Sequencing 
KIT and the instrumentation Ion Torrent PGM and compared the results with articles from 
literature (Somatic mutation and gain of copy number of PIK3CA in human breast cancer. 
Guojun Wu 2005) and with 2 databases: Cosmic.org 
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) and TP53 databases (http://p53.fr)  
results in Table 2.  We found that 11 seminal mutations were differently represented in the 11 
cell lines evaluated.  
MTOR, the mammalian target of rapamycin, was present in 5 lines over 11. MTOR is the 
catalytic subunit of two structurally distinct complexes: MTORC1 and MTORC2, and in 
particular is a serine/threonine protein kinase, which belongs to the phosphatidylinositol 3-
kinase-related kinase protein family and regulates cell growth, cell proliferation, cell motility, 
cell survival, protein synthesis, and transcription.  MTOR integrates the input from upstream 
pathways, including insulin, growth factors (such as IGF-1 and IGF-2), and amino acids,  
senses cellular nutrient, oxygen, and energy level. MTOR stimulates several proteins, 
including AkT/PKB, and PKC, strongly affecting autophagy, apoptosis and tumor metastasis.   
We found mutations of PIK3CA in 6 cell lines. The phosphatidylinositol-4,5-bisphosphate 3-
kinase, catalytic subunit alpha, also called p110α protein, is a class I PI 3-kinase catalytic 
subunit, which uses ATP to phosphorylate phosphatidylinositols (PtdIns), PtdIns4P and 
PtdIns(4,5)P2. This gene  has been found to be oncogenic and has been implicated in cervical 
cancers.  
PTEN is present in a mutated form only in 1 cell line. PTEN acts as a tumor suppressor gene 
through the action of its phosphatase protein product. The protein encoded by this gene is a 
phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase this protein preferentially 
dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of 
phosphatidylinositol-3,4,5-trisphosphate in cells and regulating Akt/PKB signaling pathway. 
It contains a tensin-like domain as well as a catalytic domain similar to that of the dual 
specificity protein tyrosine phosphatases  and actually behaves as a dual-specificity protein 
phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. 
PTEN functions as a tumor suppressor by negatively regulating the PI3K-AKT/PKB signaling 
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pathway through phosphoinositides  dephosphorylation and thereby modulating cell cycle 
progression and cell survival. 
KIT mutations occur in 2 cell lines. KIT is a Tyrosine-protein kinase that acts as cell-surface 
receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell 
survival and proliferation, stem cell maintenance, and other cell functions. In response to 
KITLG/SCF binding, KIT can activate several signaling pathways: it Phosphorylates PIK3R1, 
PLCG1, SH2B2/APS and CBL, activates the AKT1 signaling pathway by phosphorylation of 
PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. The Activated KIT also 
transmits signals via GRB2 and activation of RAS, RAF1 and the MAP kinases 
MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members 
STAT1, STAT3, STAT5A and STAT5B. 
Mutations in the proto-oncogene MET occur in 2 cell lines. MET (Mesenchymal epithelial 
transition factor), also known as hepatocyte growth factor receptor (HGFR) is a proto-
oncogenic receptor tyrosine kinase. The endogenous ligand for MET is hepatocyte growth 
factor/scatterfactor (HGF), a disulfide-linked heterodimeric molecule produced predominantly 
by mesenchymal cells. In the adult, MET expression is limited to stem and progenitor cells 
and is necessary for wound healing and hepatocyte regeneration. In the embryo, MET 
receptors are expressed on cells of epithelial origin. They are essential for invasive growth 
and mediate epithelial-mesenchymal transition (EMT). Aberrant activation of the HGF/MET 
pathway leads to a variety of cancers. MET mutation is associated with a poor prognosis as it 
can trigger tumor growth, angiogenesis and metastasis.  
Four cell lines showed mutations on TP53. TP53 encodes for a transcription factor, p53, 
whose protein levels and post-translational modification state change in response to cellular 
stress (such as DNA damage, hypoxia, spindle damage). Activation of p53 begins through a 
number of mechanisms including phosphorylation by ATM, ATR, Chk1 and MAPKs.  
KDR, (5 lines on 11) (kinase insert domain receptor) is a gene encoding for a tyrosine-protein 
kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Though the 
activation of PLCG1 it leads to the production of the cellular signaling molecules 
diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. KDR 
mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling 
pathway, as well as of the AKT1 signaling pathway.  
IDH2, (1 line on 11) is a isocitrate dehydrogenases which catalyzes the oxidative 
decarboxylation of isocitrate to 2-oxoglutarate at mitochondrial level. It plays a role in 
intermediary metabolism and energy production. This protein may tightly associate or interact 
with the pyruvate dehydrogenase complex. MLH1, (1 line on 11) was identified as a locus 
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frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). It is a human homolog 
of the E. coli DNA mismatch repair gene mutL. It heterodimerizes with PMS2 to form MutL 
alpha or MutS beta binding to a dsDNA mismatch, then MutL alpha is recruited to the 
heteroduplex. MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA, 
activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch 
and thus generates new entry points for the exonuclease EXO1 to degrade the strand 
containing the mismatch. It is also implicated in DNA damage signaling, a process which 
induces cell cycle arrest and can lead to apoptosis in case of major DNA damages. 
Only one line has a mutation in BRAF. This gene encodes a protein belonging to the raf/mil 
family of serine/threonine protein kinases. This protein plays a role in regulating the MAP 
kinase/ERKs signaling pathway, which affects cell division, differentiation and secretion. 
Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease 
characterized by heart defects and mental retardation. Mutations in this gene have also been 
associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, 
malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma 
of lung. KRAS results mutated only in one cell line. This gene, a Kirsten ras oncogene 
homolog from the mammalian ras gene family, encodes a protein that is a member of the 
small GTPase superfamily. A single amino acid substitution is responsible for an activating 
mutation. The transforming protein that results is implicated in various malignancies, 
including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and 
colorectal carcinoma.  
We have evaluated the expression level of 34 miRNAs in 8 breast cancer cell lines. We have 
employed miRNA microarrays. The results are reported in Table 3. 
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Cell line ZR75.1  MCF7  HBL100 
MDA-
MB-361 184A1 MCF10A 
MDA-MB-
453 SKBR3 
MDA-MB-
231 
MDA-MB-
468 T47D 
Receptor 
Status 
ERα+, PR+ 
HER2-  
ERα+,  
PR+ 
HER2+ 
ERα-, 
PR- 
HER2+ 
ERα+, 
PR+ 
HER2+ 
TN           TN             ERα- PR-
HER2+       
ERα-,  
PR- 
HER2+ 
TN TN ERα+, 
PR+ 
HER2- 
MTOR 
het, 
E2363G  Wt wt 
het, 
E1427Q 
het, 
Q1627K wt  deletion Wt wt Wt 
hom, 
L955X 
 MTOR 
(2nd) 
het, 
K1753R       
het, 
L955X   A954fs         
PIK3CA het, E545K het, E545K 
het, 
I391M 
het, 
E545K wt wt het, H1047R Wt wt Wt 
het, 
H1047R 
KIT het, R49C Wt wt wt 
het, 
M541L wt wt Wt wt Wt wt 
MET 
het, 
V1218A Wt 
het, 
E168D wt wt wt wt Wt wt Wt wt 
TP53 wt Wt wt wt wt wt wt het, R43H het, R148K het, R141H het, L62F 
 TP53 
(2nd)                 het, R280K het, R273H   
PTEN  wt Wt wt wt wt wt het, E307K Wt wt wt  wt 
IDH2 wt Wt wt wt 
het, 
M131V wt wt Wt wt Wt Wt 
KDR  wt Wt 
het, 
N274S wt wt wt het, V297I Wt het, V297I hom, V297I 
hom, 
V297I 
MLH1  wt Wt wt wt wt wt wt het, S165N wt Wt Wt 
BRAF wt Wt wt wt wt wt wt Wt het, G464V Wt Wt 
KRAS wt Wt wt wt wt wt wt Wt het, G13D Wt Wt 
 
Table 2.  In table 2 is reported the list of the cell lines, with the estrogen receptor ERα positive (+) or negative (-), progesterone receptor PR ( + positive, - negative), human 
epidermal growth factor receptor 2 (HER2 + positive or – negative), TN indicate triple negative for ERα, PR and HER2,  and the correspondent list of mutant genes. In each 
square it is indicated the status of the protein (wt = wild type), the zygosity (hom = homozygosy, het = hetrozygosity) and the letters and the number indicate the position and 
the change of the correspondent aminoacid.
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MCF
7  
T47
D  
BT-
474  
MCF-
10A  
MDA-MB- 
231  
SKBR
3  
MDA-MB- 
468  
MDA-MB- 
453  
Complessiv
e 
let-7d + + + + + + + + + 
miR-103 ++ ++ ++ ++ ++ ++ ++ ++ ++ 
miR-106a + ++ + + ++ ++ ++ ++ ++ 
miR-106b + + + + + + ++ + + 
miR-10a - + + ++ + ++ - -   
miR-126 - - + + - + - - - 
miR-130b - ++ ++ ++ + ++ + ++ ++ 
miR-138 + + ++ ++ ++ + - - + 
miR-145 - + + + - - - - - 
miR-148b - - + - - - - + - 
miR-151 - - - - - - - - - 
miR-17 + ++ + + ++ ++ ++ ++ ++ 
miR-181a + ++ - - ++ ++ ++ ++ ++ 
miR-18a - - - - - - - - - 
miR-197 ++ + ++ ++ ++ ++ ++ ++ ++ 
miR-203 ++ ++ ++ + - - + ++ ++ 
miR-206 + + + + + - + + + 
miR-21 ++ + ++ + ++ ++ ++ ++ ++ 
miR-210 + + + + + - + + + 
miR-218 - - - - - - - - - 
miR-222 - - ++ ++ ++ ++ ++ - ++ 
miR-224 - - - - - - - - - 
miR-25 ++ ++ ++ ++ ++ ++ ++ ++ ++ 
miR-26b ++ ++ ++ ++ ++ ++ ++ ++ ++ 
miR-27a + + ++ - + + + + + 
miR-28-
5p - - - - - - - - - 
miR-301a + + ++ ++ + ++ ++ - ++ 
miR-30a + ++ ++ ++ ++ + ++ ++ ++ 
miR-320 ++ ++ + ++ + ++ ++ ++ ++ 
miR-326 - - - - - - - - - 
miR-328 ++ + ++ ++ + + + + + 
miR-9 - + + + - - + + + 
miR-93 + + + + + + ++ ++ + 
miR-99a + + + ++ ++ ++ + + + 
 
Table 3. Level of expression of a list of miRNAs in breast cancer cell lines indicated. – indicated absent level of 
miRNA, + indicates normal level, and ++ represent an over-expression of miRNA in cell lines reported. 
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3.2.  Curves of growth for MDA-MB-231 and for MCF7 
 
To test the ideal number of cells to seed into 96 well, for the following experiment of 
transfection of selected miRNAs , we performed curves of growth with different 
concentrations of cells at time T0, T24, T48, T72h. We used MDA-MB-231 and MCF7 
because these cells are representative of all other cell lines, the first is the smaller with a 
diameter of 6 µm and the second is the bigger with a diameter of 16 µm. To see the effect of a 
miRNA on viability, the cells into the well had to be at 50% of confluence. The cells were 
seed in 10% FBS medium at concentration of 4x10
3
, 6x10
3
, 8x10
3
, 1x10
4
 into 96-plate, each 
in quadruplicated. The experiment was repeated three time. At the time indicated, we 
measured the OD (optical density) read at 492 nm after 4h of incubation with MTS salt. In 
Fig. 9, A and B  we reported the mean of OD, for MDA-MB-231 and MCF-7.                           
For both cell lines, MDA-MB-231 and MCF7, as shown in the histograms, the best 
concentration of cells seeded in 96 well is 6x10
3
, because allowed a  linear  curve of growth is 
during the explored time, while at  the concentration of 8x10
3
 and 1x10
4
 OD reading reached 
confluence plateau. 
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  A 
                             
 
B     
 
Figure 9. Histogram representation of curves of growth for MDA-MB-231 (A) and MCF7 (B). 
 
3.3. Efficiency of transfection  
To test the transfection efficiency reached in the cell line that we have used in this study,  we 
have seed cells in 24 well, and when cells reached the concentration of about 80%, using the 
agent lipidic transfectant siPort, we have introduced into cells a plasmid vector containing the 
green fluorescence protein EGFP. After 48h and 72h from transfection, cells appeared green 
under fluorescence microscopy. The results have shown that the mean efficiency of 
transfection for all cell lines explored was 70+/-5%. As shown in  Figure 10,  after 72h from 
transfection, the major part of the cell line MDA-MB-231, MCF7 and BT474 appeared green 
in fluorescence, demonstrating an high transfection percentage.  
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Figure 10. In figure are shown the images of cells:  A- MDA-MB-231; B- MCF7; C- BT474, transfected with 
EGFP. 
 
 
3.4. Viability regulation by miRNAs  
The functions of microRNAs in regulating cell growth and proliferation have been well 
established in recent years because they can target genes involved in cell proliferation. For 
example, down regulation of miR-143 and miR-145 in different types of cancers suggests 
their role in controlling cell proliferation serving as tumor suppressor. In contrast, the up 
regulation of miR-21 and miR-210 in many cancers suggests their role as oncogene. For this 
reason, we have investigated the effect of 23 selected miRNAs (see Table 4) that were over- 
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or down-expressed in different types of tumors respect to normal tissues (81), on breast cancer 
cell lines.  
 
 
Table 4.  Selected miRNA used for transfection experiments. It is reported the level of expression up or down-
regulated in solid cancers respect to normal tissue. 
 
  
To simplify data presentation, a comprehensive report is given in supplementary results (S3), 
while Table 5 shows only the results of the transient transfection of 13 miRNAs all having a 
significant effect on cell viability in more than one cell line. The presented data show the 
miRNAs having an outlier 2 effect, e.g. whose effect on cell viability, (measured as MTS 
absorbance) was greater (red boxes) or lower (green boxes) than median plus or minus 2 
MAD. In addition, in the table the star * indicates which miRNA has an outlier 3 effect while 
miRNA name in bold indicates miRNA listed as up-regulated in Table 5. It is possible to see 
that miRNAs up-regulated in tumors (miR-26, miR-130b and miR-210) increase cell viability 
miRNA Expression in  
solid tumors  
hsa-miR-126* Down-expressed 
hsa-let-7d* Down-expressed 
hsa-miR-326 Down-expressed 
hsa-miR-320c Down-expressed 
hsa-miR-302a Over-expressed in embryonic tissues 
hsa-miR-222 Over-expressed 
hsa-miR-218 Down-expressed 
hsa-miR-210 Over-expressed 
hsa-miR-206 Down-expressed 
hsa-miR-203 Down-expressed 
hsa-miR-202 Down-expressed 
hsa-miR-181a Down-expressed 
hsa-miR-142-5p Down-expressed 
hsa-miR-145 Down-expressed 
hsa-miR-143 Down-expressed 
hsa-miR-138 Down-expressed 
hsa-miR-130b Over-expressed 
hsa-miR-126 Down-expressed 
hsa-miR-99a Down-expressed 
hsa-miR-28-5p Down-expressed 
hsa-miR-33b Down-expressed 
hsa-miR-26b Over-expressed 
hsa-miR-21 Over-expressed 
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and so cluster in the group of growth-stimulating miRNAs, while the down-regulated 
miRNAs (miR-145, miR-28-5p, miR-126, miR-181a, miR-203, miR-206, miR-326), when 
administered to cells,  resulted to give a decrease in cell proliferation. MiR-99a, miR-138 and 
miR-143, although down-regulated in tumors, when restored in cell line culture, originated an 
apparently paradoxical effect by determinating an increase of cell viability. It is to note that 
miR-99a is reported in literature to be highly expressed in several cell lines. This suggest that 
in cell lines at least miR-99a, and possibly also miR-138 and miR-143 act as growth-
stimulating factors, and, when added, further exert this action. 
In addition, we can see as miR-99a and miR-210 increased cell viability preferentially in 
p53wt cell lines, while miR-138 had is effect on 4 p53mut over 5 cell lines. MiR-130b and 
miR-143 did not show any preference equidistributing their effect on p53wild type or mutant 
cell lines, while miR-26 increased cell proliferation only in p53mut, triple negative lines. For 
miRNAs able to decrease cell viability, only miR-28-5p and miR-206 exerted their effect only 
in p53mut lines, while all the others did not show preference for a particular p53 status. 
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ZR75.1  MCF7  HBL100 BT474 
MDA-MB-
361 184A1 MCF10A 
MDA-MB-
453 SKBR3 
MDA-
MB-231 
MDA-
MB-468 T47D Tot 
 
P53+ P53+ P53+ P53+ P53+ P53+ P53+ P53- P53- P53- P53- P53- cell lines 
 
ERα+ PR+ 
HER2-  
ERα+ PR+ 
HER2+ 
ERα- PR- 
HER2+ 
ERα+ PR+ 
HER2+ 
ERα+ PR+ 
HER2+ 
TN TN  ERα- PR-
HER2+  
ERα- PR- 
HER2+ 
TN TN ERα+ PR+ 
HER2- responsive 
 
          NI NI NI           
hsa-miR-26b                   *     2 
hsa-miR-99a                         4 
hsa-miR-130b     *             *     5 
hsa-miR-138   *             * * *   5 
hsa-miR-143       *                 2 
hsa-miR-210   * *                   5 
hsa-miR-145   *           *         5 
hsa-miR-28-5p               *         2 
hsa-miR-126   *           *         5 
hsa-miR-181a   *       *         *   3 
hsa-miR-203           *       *     3 
hsa-miR-206             * *         2 
hsa-miR-326 *             *         2 
 
Table 5. Table 5 reports the miRNA having an outlier 2 effect, e.g. whose effect was greater (red boxes) or lower (green boxes) than median plus or minus 2 MAD, as 
reported in M&M. The star indicates which among miRNA shows also an outlier 3 effect. The miRNA name in bold indicates that miRNA is up-regulated in solid tumor, as 
indicated in table 2.  For space pressure, the mirna having significant effect only in 1 cell lines or no effect at all are not showed in this table. Complete data are in 
supplementary material (S3). 
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3.5. Effect of co-transfection of selected miRNAs  
 
Once measured the regulative effect of miRNA transfection on cell viability, of, we have 
selected three miRNAs that resulted to have a stimulatory role on cell viability, , and three 
giving an opposite effect in the most part of cell lines analyzed. The three proliferating miRs 
in the most part of cell lines tested were: miR-130b, miR-138, miR-210; the three inhibitory 
miRs were: miR-26b, miR-126, miR-145. So, we performed experiments of co-transfection 
using the selected miRNAs or alone or pooled together in a 3 miRNA mix and evaluated their 
effects on cell viability. We  choose for these experiment MCF7, MDA-MB-468, MCF10A, 
HBL100, MDA-MB-361,MDA-MB-453, being these cell lines more sensitive to the above 
reported miRNA. In these cell lines miR-130b and miR-210 are normally over-expressed. 
Nevertheless, and consistently with Table 5, we saw that miR-130b, miR-138, miR-210, 
administered as miRNAs alone increased cell viability. We observed also that, administering 
all the three miRNAs in a whole mix, with a total miRNA concentration (100 nM) identical to 
the one used  for miRNA alone,  there was no additive effect, suggesting that all the three 
miRNA evaluated probably act on similar targets, perhaps already  maximally stimulated, or 
on targets located on the same pathways. Result could be explained noting that in cell lines 
the miRNA resulted already to be normo- or over-expressed; it is so reasonable that the gain 
of viability obtained by transfecting single miRNAs cannot be over-passed. Furthermore, 
when we used the mix of the three inhibiting miRNAs, we saw a significant decrease of living 
cells respect to the inhibiting miRNAs administered alone. This significant gain of effect 
obtained with anti-proliferating miRNAs suggests either that these miRNA can act on 
different parts of the cell machinery regulating cell viability, or that at the concentration used 
in these experiments they are again far to exert their maximal inhibitory activities. In 
particular, this significant effect has been seen for MCF7, HBL100, MDA-MB-361 and 
MDA-MB-453, but this not in MCF10A and MDA-MB-468. These results are reported in 
Fig. 11. 
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Figure 11. Figure 11 reports MTS results of the three selected miRNAs whose effect increase cell viability 
(miR-130b, miR-21, miR-210) or decreased it (miR-26b, miR-126, miR-145. These miRNAs were administered 
alone or r in combination (miR-130b, miR-21, miR-210, mix A, and  miR-26b, miR-126, miR-145, mix B) a) in 
MCF7, MDA-MB-468, MCF10A, HBL100, MDA-MB-361, MDA-MB-453. All experiment were performed in 
triplicate.  
 
3.6. Viability regulation by prognosis-related  miRNAs  
We also have tested the effect of others 15 miRNAs that are implicated in the prognosis of the 
breast cancer (Table 6) (82). These miRNA are: hsa-miR-93, hsa-miR-1307, hsa-miR-148b, 
hsa-miR-328, hsa-miR-484, hsa-miR-874, hsa-miR-10a, hsa-miR-27, hsa-miR-615, hsa-miR-
9, hsa-miR-25, hsa-miR-301a, hsa-miR-30a, hsa-miR-151, has-miR-103. These miRNAs 
adversely impacted on prognosis, i.e. an  increase of expression decreased patients’ overall 
survival. Among these miRNAs, miR-10a and miR-30a are related to lymph node metastasis. 
In fact miR-10a is over-expressed in primary tumors of patients who have positive lymph 
nodes (N+ stage), while miR-30a have the opposite behavior. We have performed experiment 
of transfection using 100 nM concentration of miRNAs. Results are summarized in Table 7, 
which shows only the results of the transient transfection of 11 miRNAs all having a 
significant effect on cell viability in more than 1 cell line. The presented data show the 
miRNAs having an outlier 2 effect, e.g. whose effect on cell viability was greater (red boxes) 
or lower (green boxes) than median plus or minus 2 MAD. In addition, the table indicates 
which miRNA has an outlier 3 effect (*). The first consideration is that, differently from what 
reported for proliferation-related miRNAs, the prognosis-related miRNAs did not show any 
apparent clustering according to p53 status. In fact, they exert their role independently from 
the presence or absence of p53 mutations, and are randomly scattered in the whole table 
(Table 7). Among the miRNAs, miR-148 and miR-1307 resulted to promote cell growth in 5 
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different lines, and with 3 and 2 outlier each one, respectively. MiR-484 and miR-27 
stimulated cell growth in just 2 cell lines, while miR-301 and miR-9 gave non uniform results, 
behaving as stimulatory in some lines and anti proliferating in others. Unexpectedly, miR-93, 
miR-30a, miR-103 and miR-874 inhibited instead of  stimulate cell proliferation. This effect 
was particularly evident for miR-93, which decreased cell viability on 5 lines over 10, also 
with outlier 3 effects. 
 
miRNA Association with prognosis 
hsa-miR-9 Over expressed and associated with metastasis in BC (ref. Wang J et al. Cancer 
Biotherapy & Radiopharmaceuticals. Overexpressions of MicroRNA-9 and 
MicroRNA-200c in Human Breast Cancers Are Associated with Lymph Node 
Metastasis.  May 2013, 28(4): 283-288 
hsa-miR-10a Associated with Lymph Node Metastasis (Volinia et al, unpublished results) 
hsa-miR-25 Increased level of miR-25 expression is 
associated with a poor overall survival (Xiaojun Li et al. Med Oncol (2014) 31:781 
The expression of miR-25 is increased in colorectal cancer and is 
associated with patient prognosis. 2012, 7(12): e51702 
hsa-miR-27 High miR-27a expression is associated with poor overall survival in patients with 
breast cancer (Wei Tang et al. PLOS ONE MiR-27 as a Prognostic Marker for Breast 
Cancer Progression and Patient Survival 
hsa-miR-30a Associated with Lymph Node Metastasis 
(Volinia et al, unpublished results) 
hsa-miR-93 Association with overall survival (Cox Regression) (Volinia et al, unpublished results) 
hsa-miR-103  
hsa-miR-148b Association with overall survival (Cox Regression) (Volinia et al, unpublished results) 
down-expressed in lines!! 
hsa-miR-151 Association with Drug Resistance (Cox Regression)  
(Volinia et al, unpublished results) down-expressed in lines!! 
hsa-miR-301a Association with Drug Resistance (Cox Regression) 
(Volinia et al, unpublished results) 
hsa-miR-328 Association with overall survival (Cox Regression) (Volinia et al, unpublished results) 
hsa-miR-484 Association with overall survival (Cox Regression) (Volinia et al, unpublished results) 
hsa-miR-615 Association with overall survival (Cox Regression) (Volinia et al, unpublished results) 
hsa-miR-874 Association with overall survival (Cox Regression) (Volinia et al, unpublished results) 
hsa-miR-1307 Association with overall survival (Cox Regression) (Volinia et al, unpublished results) 
 
Table 6. In table 6 are reported the list of miRNAs that are related to prognosis of cancers. 
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ZR75.1 MCF7 HBL100 
MDA-MB-
361 184A1 MCF10A 
MDA-
MB-453 
SKBR3 
MDA-MB-
231 
MDA-
MB-468 T47D 
Tot 
Responsive 
Cells 
 
                        
hsa-miR-9   *     nd *           5 
hsa-miR-27         nd   *         2 
hsa-miR-30a                       2 
hsa-miR-93     * Nd       *       5 
hsa-miR-103     * Nd               2 
hsa-miR-148b *         * *       * 5 
hsa-miR-301a        
 
nd     *       3 
hsa-miR-484                        2 
hsa-miR-615   *     nd *       *   4 
hsa-miR-874       Nd               2 
hsa-miR-1307         * *           5 
 
Table 7. Table 7 reports the miRNA having an outlier 2 effect, e.g. whose effect was greater (red boxes) or lower (green boxes) than median plus or minus 2 MAD, as reported in 
M&M. The star indicates which among miRNA shows also an outlier 3 effect. For space pressure, the mirna having significant effect only in 1 cell lines or no effect at all are not 
showed in this table. Complete data are in supplementary material (S4). 
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In Table 8 are presented some summary data, including miRNA expression level in tumors, in 
cells and the miRNA effect on cell viability, detected as MTS assay.  
 
miRNA  Tumors Cell lines Viability 
hsa-miR-326 Down-expressed - ↓ 
hsa-miR-145 Down-expressed - ↓ 
hsa-miR-126 Down-expressed - ↓ 
hsa-miR-28-5p Down-expressed - ↓ 
hsa-miR-126* Down-expressed - ns 
hsa-miR-218 Down-expressed - ns 
hsa-miR-138 Down-expressed + ↑ 
hsa-miR-99a Down-expressed + ↑ 
hsa-miR-206 Down-expressed + ↓ 
hsa-let-7d* Down-expressed + ns 
hsa-miR-203 Down-expressed ++ ↓ 
hsa-miR-181a Down-expressed ++ ↓ 
hsa-miR-320c Down-expressed ++ ns 
hsa-miR-143 Down-expressed nd ↑ 
hsa-miR-202 Down-expressed nd ns 
hsa-miR-142-5p Down-expressed nd ns 
hsa-miR-33b Down-expressed nd ns 
hsa-miR-210 Over-expressed + ↑ 
hsa-miR-130b Over-expressed ++ ↑ 
hsa-miR-26b Over-expressed ++ ↑ 
hsa-miR-222 Over-expressed ++ ns 
hsa-miR-21 Over-expressed ++ ns 
   
Table 8. This table summarizes previously presented data regarding the miRNA expression levels in 
tumor, cell lines, and miRNA effect on cell viability after transfection. +: normal level of expression; 
++: over-expression of miRNA; - miRNA absent or down-expressed; nd: not determined.  ns: not 
significant change ↑: increase of cell viability (2 MAD outlier); ↓ decrease of cell viability (2 MAD 
outlier).  
 
Five miRNA are over-expressed in tumors, among them 4 are also over-expressed in cell 
lines, and 3 (miR-210, miR-130b and miR-26b) strongly increased cell viability, while no one 
decreased it. In the group of 17 miRNAs down-expressed in tumors, 6 are also down-
expressed in cell lines. When these are restored by transfection in cells, 4 of them (hsa-miR-
326, hsa-miR-145, hsa-miR-126, hsa-miR-28-5p), could significantly depress cell viability. 
Overall, 7 miRNA over 17 decreased cell viability, and only 3 miRNA strongly stimulated 
cell viability. Starting from the whole data, the Fisher Exact Probability Test estimates as not 
significant the association between viability stimulation (or depression) and the tumor level.  
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3.7. Wound healing assay 
From analysis of MTS assay, we have selected the miRNA that gave a major effect in a great 
number of lines and analyzed their regulatory role on  cell  migration. This miRNA awere: 
miR-138, miR-130b, miR-21, miR-210, miR-26b, miR-148, miR-1307, miR-99, miR-222, 
miR-126. By wound healing assay, we have tested their activity on the following cell lines: 
T47D, MDA-MB-468, SKBR3, MDA-MB-453, MCF7, MDA-MB-231, MCF10A, ZR751.   
Table 9 summarizes the wound healing assay results. In the cell lines tested, both miR-1307 
and miR-21 increased both cell proliferation and migration, while miR-138, and miR-26 had a 
positive effect on proliferation but didn’t show any effect on migration. MiR-130b 
significantly increased cell migration in SKBR3, line in which it was shown to increase also 
cell proliferation. On the other hand, the same miRNA failed to significantly increase cell 
migration in MCF7, MDA-MB-231, and ZR75.1, while in all these lines it significantly 
increased cell proliferation, suggesting a prevalence of the role of the miRNA on 
proliferation. 
MiR-210 in MCF7, ZR75.1 and MDA-MB-468 increased cell viability but showed a different 
effect on cell migration in the 3 different lines tested: in fact, in the first cell line it increased 
cell migration while in the second significantly decreased it and finally in the third had no 
effect.  
MiR-148 decreased cell migration in 3 of the 6 lines tested, had no effect on 2, and just in 1 
augmented migration, while it increased proliferation in 5 lines over 6.  
The images from which it was summarized the Table 9, are reported in supplementary 
materials (figure S1).  
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ZR75.1  MCF7  HBL100 MCF10A MDA-MB-453 SKBR3 MDA-MB-231 MDA-MB-468 T47D 
 
  
   
 
    hsa-miR-9 nd ↓ nd nd nd nd nd nd nd 
hsa-miR-10a nd nd ↓ nd nd nd nd   nd 
hsa-miR-21 nd nd nd nd nd nd  ↑ nd nd 
hsa-miR-126 nd nd nd nd ↓ nd nd nd nd 
hsa-miR-130b ↑ ↑   nd nd  ↑ ↑ nd   
hsa-miR-138 nd nd nd nd nd ↑ nd nd ↑ 
hsa-miR-148 ↑ ↑ nd  ↑ ↑ nd nd 
 
↑ 
hsa-miR-210 ↑  ↑   nd nd nd   ↑ nd 
hsa-miR-1307 nd   nd  ↑ nd nd nd nd  ↑ 
 
Table 9.  Wound healing assay. In red are shown the miRNAs that gave a significant (t testp<0.05)increase of migration when analyzed by 
wound healing assay, in green the miRNAs that give a significant (t testp<0.05) decrease of migration. In blank  are indicated the miRNAs that 
do not give any effect on migration. nd = not done. To make comparison easier, the miRNAs effects on viability, and already reported in tables 4 
and 6,  were superimposed.  Arrows refer to significant changes in cell viability measured with MTS assy: ↑ viability increase; ↓ viability 
decrease. The result of all the miRNAs tested are reported in supplementary (S5).
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3.8. Real time measurement of cell invasiveness and cell proliferation  
We have chosen miRNAs that showed significant effect on viability and on migration after 
MTS and wound healing assay, and  have investigated their activity on proliferation and on 
invasion through a matrix using an electronic, impedance-based, measurement systems 
designed to evaluate changes in cell behavior.  
Changes in cellular morphology or growth rate can be early indicators of adverse cellular 
events. Detection and quantization of these events with impedance-based cell sensing 
measurement systems appear to offer improved, real-time, label-free and non-invasive 
analysis of key cellular events. When adherent cells attach and spread across the sensor 
surface of an electrode, increases in impedance are recorded. Conversely, cells that round up 
or detach even for a short time will cause impedance values to drop. In addition, different 
setting of this system can measure simple cell proliferation or cell motility through a Matrigel 
support. The apparatus  is the xCELLigence™ System from Roche Applied Science (Real-
Time Cell Analyzer System, Roche Applied Science, Mannheim, Germany). For these 
experiments we used the  poorly invasive ERα-positive, p53 wild type, and luminal epithelial-
like cell line MCF7. 
MCF7 were treated with miR-148, and miR-126 and control (miRNA scramble), to test their 
capability to stimulate cell movement through Matrigel layer (cell invasiveness). On the other 
hand, to independently confirm previous data on cell viability using this proliferation-specific 
approach, we tested miR-9, miR-130, miR-138, miR-145, miR-1307.  
MiR-126 was under-expressed both in tumors and in MCF7; when restored by transfection, it 
showed to slightly but significantly decreased cell spreading, as measured by xCELLigence™ 
System. The MCF7 cells were also treated with miR-148,which showed a positive effect on 
cell invasion. This is consistent with the proliferative effect revealed by MTS assay, but not 
with results obtained by wound healing screening. This can be partly explained by the fact 
that wound healing assay was performed in the presence of 0.1% serum. In this conditions 
miR-148 was showed to increase proliferation, but impair cell spreading. In the 
xCELLigence™ System, the invasion assay was performed using as chemo attractor medium 
containing 10% serum. This particular condition can have sustained cell spreading more than 
we have detected in wound healing assay in the presence of 0.1% serum  
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To further confirm the results obtained with MTS assay, we used xCELLigence™ System 
also to measure cell proliferation. In this case, culture conditions employed 48h of 
transfection in 0.1% serum  followed by 72h growth in 10% serum after. Interestingly, both 
miR-9 and miR-145, which strongly decreased cell growth in 0.1% serum, actually reduced 
cell impedance also in the presence of 10% serum. Similarly, miR-130, miR-138 and miR-
1307, a strong proliferative miRNA, were able to further increase cell impedance also in the 
presence of 10% serum.  Each condition was performed in quadruplicate with a programmed 
signal detection every 15 min for a total of 96 h. Impedance values were converted into a 
dimensionless parameter termed cell index (CI) M&M.  
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3.9. mRNA profiling after miRNA treatment 
 
MiR-145 appear to display a coherent behavior in different models: in fact, it is down-
regulated in tumors and in BC cell lines, this suggesting a possible role in the inhibition of 
tumor growth; consistently, it in vitro reduced strongly BC cell line viability and proliferation, 
as established by MTS and xCELLigence assays.  In the attempt to better characterize the 
inhibitory activity that miR-145 exerted on cancer cell growth, we analyzed the gene 
expression profiling of several cell lines, MDA-MB-231 (p53 mut), MCF7 (p53 wt), MDA-
MB-361 (p53 wt), MDA-MB-453 (p53 wt) versus scramble treated cells.     
MiR-145 showed to be greatly interestingly, because it induced a significant  (p< 0.001) 
variation of the expression of 736 genes in miR-145 versus scramble-treated cell lines. 
Among them, miR-145 induced a strong increase in mRNA expression of a group of 
polymorphic genes located on chromosome 6. These genes are all related to immune 
response, and belong to the MDH I and II family. In fact, we saw an increase in the HLA-A, 
HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H, HLA-J genes,  all members of MDH I 
family. We found also up-regulation of butyrophylin 3, a MDH I-associated gene, and of 
TAP1, a gene contained in the MHC I region codifying for a membrane transporter involved 
in the pumping of degraded cytosolic peptides across the endoplasmic reticulum into the 
membrane-bound compartment where class I molecules assemble. We found also an increase 
in HLA-DRA and HLA-DRB1, genes belonging to MHC II family and codifying for both the 
subunits alpha and beta of the dimeric MDH II complex. Complement Factor B and 
proteasome subunits 8 and 9, other genes in the MHC II region, were also found to be up-
regulated. In particular, the two IFN-inducible proteasome subunits exert a role in the process 
of antigen processing and presentation, which constitute an indispensable preliminary step in 
MHC activity. In addition, several IFN-related genes were found to be increased, and in 
particular interferon-induced proteins 6, 27, 35, 44 and 44-like (this one encoding a minor 
histocompatibility antigen), interferon-induced tricopeptides 1, 2, 3 and 5, and interferon-
induced transmembrane proteins 1, 2 and 4.  
In addition, several other IFN-dependent proteins related to immune response were over-
expressed, like as ligands for CXCR3 receptors and ligand for CXCR5 receptor. These 
chemokines can originate a pleiotropic response, including stimulation and induction  of 
migration of monocytes, NK- and T-cells, and in particular CCR5 ligand, normally produced 
by CD8+ cells,  has a recognized HIV-suppressive action. Also DEAD polypeptides 58 and 
60-like were found to be increased. The first one is a putative RNA helicase which is 
implicated in a number of cellular processes involving RNA binding and alteration of RNA 
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secondary structure. It is involved in viral double-stranded RNA recognition and the 
regulation of immune response. Another DEAD box protein, IFIH1, is a RNA helicase up-
regulated by IFN beta and mezerein, a PKC activator. Stimulation of melanoma by both these 
compound was reported to be able to reprogram cells to a non invasive, differentiated status. 
We found also up-regulation of IL29 and IL8, the related Toll-like receptor 3 and of 2'-5'-
oligoadenylate synthetase 2 and 3, normally induced by IFN, both implicated in the resistance 
to viral infection. 
Additionally, miR-145 stimulated the transcription of a member of the carcinoembryonary 
antigens, the carcinoembryonic antigen-related cell adhesion molecule 1, CEACAM 1. The 
gene product belongs to the immunoglobulin superfamily/cell-cell adhesion molecule detected 
on leukocytes, epithelia, and endothelial cells. It can have roles in the differentiation and 
arrangement of tissue three-dimensional structure, angiogenesis, apoptosis, tumor 
suppression, metastasis, and the modulation of innate and adaptive immune responses.  
Although all the reported expression changes constitute a coherent scenario suggesting the 
possibility that  miR-145 can act in vivo  inducing cells to attract members of immune 
response, or conversely that a reduction of mR-145 levels can help the tumor to escape 
immune response, anyway they do not explain the causes of in vitro miR-145 toxicity. 
Different insights may come from different expression variations, that can have a more direct 
effect in regulating citotoxicity. In fact, we found up-regulation of STAT1 and 2, two 
activators of transcription that, after homo or heterodimerization, can bind to an interferon 
stimulated promoter, activating the expression of Interferon Stimulated Genes. STAT1and 2 
can also interact with a wide number of molecules, and behave also as cell-death promoting 
agents. In fact, depending upon stimuli or cell types, STAT1 can modulate a broad spectrum 
of apoptotic and non-apoptotic pathways. STAT1-dependent regulation of cell death is largely 
dependent on a transcriptional mechanism such as the activation of death-promoting genes. 
However, non-transcriptional mechanisms such as STAT1 interaction with TRADD, p53, or 
HDAC have been implicated in the regulation of cell death by STAT1 (83).  
In addition, another possibility to increase cell death came from XIAP associated factor 1, a 
gene strongly up-regulated after miR-145 treatment. This gene encodes a protein which binds 
to and counteracts the inhibitory effect of a member of the IAP (inhibitor of apoptosis) protein 
family. In particular, IAP proteins bind to and inhibit caspases which are strong apoptosis 
effectors. The balancing between IAPs and their counteracting proteins modulate the progress 
of the apoptosis signaling pathway, and XAF1 over-expression can actually increase the cell 
death rate.  
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Another possible route may came from over-expression of sterile alpha motif domain 
containing 9, whom we found up-regulated in our samples,  while other authors found 
involved in cytotoxicity induced in gliomas by IFN beta or Sendai virus particles (84). This 
finding is of particular interest, because furnish an additional evidence that part of the cellular 
response to viral infection could reduce the viability of cancer cell too. 
In addition, we found that miR-145 strongly up-regulated  4 members of the PARP  family, 
PARP9, 10, 12 and 14. The functions of PARP-1, which promotes DNA repair but also 
mediates a caspase-independent form of apoptosis in response to stressors such as irradiation, 
are well known.  However, the biologic function of most other PARPs is not known. PARP-
14 is known to  plays a fundamental role mediating protection against apoptosis in IL-4 
treated B cells, including that after DNA damage, and mediates IL-4 effects on the levels of 
gene products that regulate cell survival, proliferation, and lymphomagenesis (85). 
PARP-9 has recently been discovered in patients with  certain types of diffuse large B-cell 
lymphomas (DLBCL). It has been described as a new nuclear protein encoded by the BAL 
gene, which is expressed at a significantly higher level in fatal high-risk DLBCLs and may be 
implicated in B-cell migration. Up-regulated by IFN-gamma in B-cell lymphoma cell lines. 
 
We have seen also up-regulation of DTX3L, in concert with PARP9, may play a role in 
PARP1-dependent DNA damage repair. PARP1-dependent PARP9-DTX3L-mediated 
ubiquitinization and promotes the rapid and specific recruitment of 53BP1/TP53BP1, 
UIMC1/RAP80, and BRCA1 to DNA damage sites.  
 
Characteristically, miR-145 strongly increased also mRNA for phospholipid scramblase 1, a 
key enzyme responsible for the translocation of phosphatidylserine (PS) from the internal 
leaflet to the external cell surface. Being PS almost completely segregated at the cytoplasmic 
layer of cell membrane, the PS externalization constitutes a specific signal able to trigger pro-
coagulation reactions and to provide a phagocytic signal to the macrophages that engulf and 
clear the apoptotic cells. The up-regulated PPM1K gene encodes a mitochondrial 
serine/threonine phosphatase that is essential for the regulation and nutrient-induced 
activation of the branched-chain alpha-keto acid dehydrogenase complex (BCKD or 
BCKDC), which catalyzes the breakdown of branched-chain amino acids (BCAA). PPM1K 
regulates the mitochondrial permeability transition pore and is essential for cellular survival 
and development. 
Optineurin, which transcript is doubled by miR-145, is able to  interact with adenovirus E3-
14.7K protein and may utilize tumor necrosis factor-alpha or Fas-ligand pathways to mediate 
apoptosis. MiR-145 directly stimulated up-regulation of caspase 4, a key effector of apoptotic 
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response. In addition to these wide effect on transcription up-regulation, miR-145 reduced 
also the transcription of several genes. Being the  most usual action of a miRNA, the number 
of the down-regulated genes was higher than up-regulated ones (453 vs 283);  consequently 
the almost totality of cellular functions were apparently affected. Although is quite reasonable  
that this wide down-regulation  can pleiotropically affect the cell metabolism and functions, 
here we pointed out several  more interesting gene transcription alterations, dividing them into 
two groups: 
1) Impairment of mitochondrial functions:  
Down-regulation affected several genes related to energetical metabolism and mitochondrial 
functionality, and in particular coenzyme A (CoA) a molecule widely used to activate acyl 
groups. In fact, 4% of cellular enzymes use it or CoA-activated compounds.  In addition, 
miR-145 reduced mRNAs for pantothenate kinase 3, which is a regulatory enzyme in the 
biosynthesis of CoA. Additionally, aconitase 1, a cytosolic protein that represents as an 
essential enzyme in the TCA cycle catalyzing the citrate to isocitrate isomerization. A 
reduction in the activity of these enzyme could impair the TCA cycle balancing.  Other genes 
regulating the level of Acetyl-CoA are acetyl-CoA acetyltransferase 1 encoding a 
mitochondrially localized enzyme that catalyzes the reversible formation of acetoacetyl-CoA 
from two molecules of acetyl-CoA, and  pyruvate dehydrogenase kinase, located in the 
mitochondrial matrix, which regulates PD complex activity by phosphorylating it. PDC 
convert pyruvate in acetyl-CoA, which is oxidated in the TCA cycle to produce energy . Other 
mitochondrion-related gene affected by miR-145 are: glutamate dehydrogenase , 1 which 
encodes glutamate dehydrogenase protein; a mitochondrial matrix enzyme that catalyzes the 
oxidative deamination of glutamate to alpha-ketoglutarate and ammonia; mitochondrial 
ribosomal protein S25;mitochondrial fission regulator 1; peroxiredoxin 3. which encodes a 
protein with antioxidant function and is localized in the mitochondrion. Finally,  
2) solute carrier family 25,  member of the mitochondrial carrier subfamily of solute 
carrier protein genes, which product functions as a gated pore that translocates ADP 
from the cytoplasm into the mitochondrial matrix and ATP from the mitochondrial 
matrix into the cytoplasm. Impairment of signal transduction machinery 
Signal transduction  also underwent to miR-145-induced down-regulation. In fact, a wide 
number of genes were affected, including  those coding for the isoform b of protein kinase, 
cAMP-dependent(PKA), protein phosphatase 3, (protein tyrosine phosphatase, receptor type, 
F), MAPK9 and phospholipase C, isoform b4. All these enzymes are strongly involved in cell 
signaling and in the regulation of survival related pathways. Another enzyme involved in 
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second messenger metabolism is inositol polyphosphate multikinase.  It has 3-kinase, 5-
kinase and 6-kinase activities on phosphorylated inositol substrates, and plays an important 
role in the biosynthesis of inositol 1,3,4,5,6-pentakisphosphate, and has a preferred 5-kinase 
activity.  
Cell cycle progression could be affected not only through signal transduction impairment but 
also through down-regulation of cyclin G1 and U2AF 1, an homology motif kinase which 
encodes a serine/threonine protein kinase that promotes cell cycle progression through G1 by 
phosphorylation of the cyclin-dependent kinase inhibitor 1B (p27Kip1). 
 
3.10. Cross validation on breast cancer tumors from TCGA cohort 
To gain further insights on the role of miRNAs in cancer pathology, we intersected the 
expression data obtained in cell line versus data obtained from breast cancer patients. In 
particular, down-expressed genes in cell culture were intersected with inversely related to 
miRNA levels in BC patients. This strategy could be effective with miRNA which levels 
result to be up regulated in the tumor illness, like as the miR-26, miR-130b and miR-210. In 
accordance with the well known inhibitory mRNA action on transcription,  it can allow to 
detect the down-regulated genes in of the presence of high  levels of miRNAs, both in vivo 
and in vitro. This strategy yielded two tables, (supplementary S6) which listed  several genes: 
among them the more interesting resulted be PTEN, down-regulated by miR-210, and 
DICER1, down-regulated by miR-130b. The importance of PTEN is quite obvious, because 
PTEN is a tumor suppressor gene  which can dephosphorylate  phosphatidylinositol-3,4,5-
trisphosphate to its lipid precursors; additionally, PTEN can act also as dual specificity 
protein tyrosine phosphatases. As a whole it can negatively regulate the PI3K-AKT/PKB and 
thereby modulate cell cycle progression and cell survival e this protein preferentially. This 
action has been demonstrated in several tumors and specifically in BC. It is to note that the 
cell lines selected for Affymetrix analysis were all PTEN wt lines, so the identification of a 
gene not only common to these lines and tumor patients, but probably not mutated  in the 
majority of patients, is of particular interest, because it strongly suggests  an active role of 
miRNA involvement in the maintaining of the tumor phenotype.  
This consideration can correctly reframe the involvement of DICER1 in the tumor illness. 
DICER1 is a RNAse III enzyme able to cleave the pre-miRNA hairpin at  the 3' end, cutting 
away the loop joining the 3' and 5' arms, and yielding a  miRNA duplex  of the desired length. 
This step is crucial for the correct activity of the RNA silencing complex, so any down-
regulation of DICER1 levels can greatly affect and impair the normal epigenetic control. 
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4. Discussion 
 
The general feature of cancer is the loss of cell identity and aberrant proliferation. 
Characteristically, cancer initiation and progression  is driven by the accumulation of 
mutations in protein encoding genes functioning like oncogenes or tumor suppressors. A new 
class of non-protein coding, endogenous, small RNAs has been discovered, and were found to 
be important regulatory molecules in animals and plants. These molecules, named 
microRNAs, are important post-transcriptional regulators of gene expression that control 
diverse physiological and pathological process. This regulation allows for fine tuning of 
cellular processes, including regulation of proliferation, differentiation and apoptosis, while 
its unbalancing is now supposed to play a key role in cancer. MicroRNAs and their targets 
seem to form complex regulatory networks. For examples, a single microRNA can bind to 
and regulate many different messenger RNA targets and, conversely, several different 
miRNAs can bind to and cooperatively control a single mRNA target. It was reported that 
more than one third of all human genes are regulated by miRNAs. Since the discovery of a 
functional RNA interference (RNAi) strategy in mammals, significant efforts have been 
undertaken to develop therapeutics that utilize this pathway. While progress has been made 
toward the design and delivery of short interfering and short hairpin RNAs for therapeutic 
gene silencing, accumulating evidence indicates that the modulation of miRNA activity also 
represents an attractive strategy. The therapeutic application of miRNAs involves two 
strategies. One strategy is directed against a gain of function and aims to inhibit oncogenic 
miRNAs, whereas the second strategy, microRNA replacement, involves the reintroduction of 
a tumor suppressor miRNA to restore a loss of function. 
 In this work, we have examined the miRNAs delivery in vitro, testing their effect on twelve 
cell lines of breast origin. We have selected the miRNAs on the basis of two criteria.  
Firstly, we have choose the miRNAs that were down or up-regulated in most part of solid 
tumors respect to normal tissue; secondly, the other group of miRNAs selected were chosen 
because their expression correlated with  the disease progression. By the fact that the miRNA 
level could directly or inversely correlate with presence or advancement of tumor does not 
indispensably imply a causative role in the disease,  we decided to transiently transfect the 
selected miRNA in vitro model for breast cancer.  Our goal was to investigate their effect, in 
order to identify miRNA able to actually affect the viability level of cells. The ratio, according 
on what stated above, is that pro-oncogenic miRNA, which are expected to be over-expressed 
into tumors and probably in our tumor-model cell lines, once transfected should positively 
increase cell growth. On the other hand, miRNA with tumor suppressor activity are expected 
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to be down-regulated into tumors and tumor-model cell lines , so it is reasonable to argue that 
the increase of intracellular miRNA levels by transfection should originate a decrease in cell 
viability. In order to have the more complete amount of starting information, we decided, as 
preliminary step, to investigate the mutational level of the cell lines and the level of the 
intracellular miRNAs. To do so, we performed a next generation sequencing analysis  on a 
Ion Torrent™ analyzer, in order to get data on genome integrity of our cell lines, and 
carefully reviewed the literature and online databanks in order to get data on miRNA levels by 
microarray in cell and to compare information on gene mutations .  
Our results clearly shows that the 13 selected breast cancer cell lines show a mutational 
profile superimposable to what reported in literature for the same cell lines. The more 
frequent mutations occurred in PI3KCA (6 out of 11), and MTOR (5 out of 11), two genes 
strongly related to tumor illness, while PTEN, which is functionally correlated on the 
previous mutations, occurred only in 1 cell line. As a whole, these three genes are involved in 
the regulation of the level of phosphatidylinositol-3,4,5-trisphosphate in cells and of the 
Akt/PKB signaling pathway. Other common mutations affected TP53 (4 out of 11) and KDR 
(5 out of 11) a gene encoding for a tyrosine-protein kinase that acts as a cell-surface receptor 
for VEGF able to stimulate protein kinase C and MAPK and AKT pathways through  the 
activation of inositide cycles. 
In addition, we carefully revisited existing databases and literature to collect the published 
data on miRNA levels in eight of our cell lines, and the obtained data, categorized as absence 
or low expression of miRNA, normal expression or over-expression, are reported in Tab 3. 
One interesting finding is that only 6 miRNAs out of 34 (miR-9, miR-10, miR-126, miR-138, 
miR-203,miR-181a) showed heterogeneous expression levels in the  different lines, while 
each one of the remaining 28 miRNA showed the same level of expression in  all the lines 
evaluated.  
After that, we analyzed the effect originated by miRNA transient transfection on cell viability. 
Among the first group of 23 tumor-associated miRNA, we identified 13 miRNAs which 
significantly changed cell viability. Among them, 6 increased and 7 decreased cell viability in 
more than 1 cell line, as reported in Table 5. Apparently, no clustering for p53 mutation or 
receptor status was observed. In particular, miR-126 and miR-145 gave the higher viability 
effects, and co-transfection with three inhibitory miRNA, miR-9, miR-126 and miR-145 gave 
significant increase in cell death, while co-transfection with proliferating miRNA did not 
show any increase. These results can be explained  in different ways: being proliferative miR-
130b and miR-21 often over-expressed, in our cell lines, it is possible that transfection could 
have easily reached the maximum effective dose of miRNA, or, more simply, the cell 
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machinery was forced to the maximum obtainable in our culture conditions. On the other 
hand, while miR-9, miR-126 and miR-145 are quite always under-expressed in cell line, 
leaving the possibility to have cumulative effects. Alternatively, they could regulate 
independent pathways with possibility of additive interaction. 
Successively, we pooled together the data concerning the level of expression in tumors, cell 
lines and the effect on viability, and obtained Table 8. The table illustrate the notion, already 
reported in the literature, that, the majority of miRNA seems to be down-regulated in tumors. 
This table showed that 6 miRNAs are over-expressed in tumors, among them 4 were also 
over-expressed in cell lines while 1 resulted norm-expressed. Of them, miR-210, miR-130b 
and miR-26b strongly increased cell viability, while no one decreased it.  It is anyway to note 
that, while the data showed in each group are by itself highly significant, the fact that of 6 
miRNAs over-expressed in tumors only 3 increased cell viability does not allow to reject the 
null hypothesis, and making possible that the increase in viability occurred just by chance. 
This does not allow us to say that of the  over-expressed miRNA can to increase cell line 
viability. Anyway, some of the tested miRNA are well known in the scientific literature, and 
are reported to positively involved in tumor growth.  
Mir-130b is a miRNA that results over-expressed in a large number of solid tumors, as 
hepatocellular carcinoma, lung carcinoma, and gastric cancer. Mir-130b results to enhance 
cell proliferation in 5 cell lines when analyzed by MTS assay. This results was confirmed also 
by xCELLigence RTCA system. Indeed, miR-130b increased the cell migration only in 2 cell 
lines when tested by wound healing assay. So, we can supports the notion that it acts as an 
onco-miRNA. The analysis of patients with different types of breast cancer and of breast 
cancer cell lines treated with miR-130b, shown that Dicer1 is one gene that is down regulated. 
Dicer1 is a ribonuclease type III, that is required for the post-transcriptional processing of 
miRNAs to their mature, functionally active form. In fact, the global miRNA levels are often 
reduced in human tumor specimens and Dicer has been identified as a tumor suppressor gene. 
The primary tumor development is accelerate when the miRNA biogenesis machinery 
components are inhibited (86). Previously study of Bi-Lan Li et al. (87) shown that over-
expression of miR-130b empower cell motility through targeting DICER1, increased cell 
viability and reduced cell death and apoptosis, leading to deregulation of miR-200 and other 
EMT-related genes. A similar effect was seen in colorectal cancer (CRC). Colangelo T et al. 
(Neoplasia, 2013), provide the evidence that miR-130b plays a pivotal role in colon 
tumorigenesis because it is frequently up-regulated in CRC, and expressed at higher levels in 
advanced tumor stages, and strongly linked to distant metastasis. 
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In the group of 17 down-regulated miRNAs in tumors, 6 were also down- regulated in cell 
lines. When these were restored by transfection in cells, 4 of them (hsa-miR-326, hsa-miR-
145, hsa-miR-126, hsa-miR-28-5p), significantly depressed cell viability. In summary, 7 
miRNA over 15 (41%) decreased cell viability, while only 3 miRNA (18%) stimulated it, 
while the remaining 33% did not have any effect. When we consider only the group of 
miRNAs capable to exert any effect on viability (7 + 3 miRNAs), we can see that 70% of 
miRNA depresses viability, and 30% increases it, independently from the expression level on 
cell lines.  
 
It is to note that, when we examined the viability variations generated in cell lines by tumor 
over-expressed miRNA versus tumor down-regulated miRNA. We found that differences 
between these two groups could be considered not significant by Fisher Exact Probability 
Test. (p= 0.0634). This means that,  when we compare the variation of cell viability originated 
by tumor up- or down-regulated miRNA, we find that these variations are not significantly 
different in these two groups. In other word, the distribution of viability variation (3 lines up 
and 0 down for tumor over-expressed miRNA, versus 7 lines down and 3 up in tumor down-
regulated miRNA) could be due to chance.  It is to note that this correlation is found when  we 
restrict our comparison only to the miRNA having a positive or negative  effect on viability.  
 
Data on tumor related miRNAs can be found in Table 7, which  showed the effect on cell line 
viability of a group of miRNA which expression levels in tumors had showed an inverse 
correlation with disease-free and overall survivals  and were associated with shorter time-to-
metastasis. The tested miRNA are not exhaustive of the number related-to-prognosis miRNAs 
(Table 6)  and include miR-21 and miR-210.  
The oncogenic miR-21, in addition to being a master regulator of cell survival and 
proliferation, is also implicated in the regulation of the breast cancer metastatic process by 
directly modeling the cell cytoskeleton via TPM1 suppression, and by indirectly regulating 
the expression of the pro-metastatic UPAR (via maspin and PDCD4 direct suppression) and 
of matrix metalloproteinases (via TIMP and PTEN inhibition). MiRNAs whose expression 
negatively correlate with prognostic endpoints are miR-210 and miR-21. MiR-210 is up-
regulated by HIF-1 transcription factor in breast cancer hypoxic regions. In breast cancer 
patients, miR-210 expression levels showed an inverse correlation with disease-free and 
overall survivals and were associated with shorter time-to-metastasis in all three subgroups 
(ER+, ER-, triple-negative) of lymph node–negative patients. MiR-21 is one of the miRNAs 
most frequently associated with poor cancer prognosis, independently of cancer type. In 
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breast cancer patients, miR-21 over-expression was correlated with advanced tumor stage, 
lymph node metastasis, and high grade and negative hormone receptor status. 
 In table 7 is possible to see  that in the group of 15 of prognosis-related miRNA,  11 miRNA 
over 15 resulted able to affect cell viability, 6 increasing and 5 decreasing it.  The strongest 
effect was obtained wit miR-148b, miR-615 and miR-1307, which had the most significant 
effect on the higher number of cell lines. MiR-9 and miR-93 resulted to be the most effective 
inhibitors of cell viability. No relevant correlations were found between the level in tumor and 
the effect on cell line viability, and in this sense is important to note that the numerosity of the 
table elements was lower than for Table 5. Although the distribution of data indicates an 
increase of viability diminution in tumor down-regulated miRNAs, and an increase in the 
other group, the p value of 0.076, although borderline, does not allow us to reject the null 
hypothesis. 
To get further confirmation of viability data through independent evaluations, we performed 
real time  measurement of cell growth and spreading. Although restricted to some among the 
more interesting genes, and only to MCF-7 cell line, this high throughput methods originated 
interesting results. Differently from viability data, which were obtained transfecting and 
growing line in 0.1% of serum, real time measurement of cell proliferation had been 
performed transfecting for 48h in 0.1% serum, and after detaching them and seeding known 
amount of cells over the electrodes in the presence of 10% of serum. The data showed that 
miR-1307 could stimulate cell growth also in the presence of serum: this confirmed the 
viability stimulating effect already detected in MCF-7, 184A1, MCF10A, SKBR and T47D, 
and suggested the possibility that this effect could be additive to the serum-induced 
stimulation, and so a specific miRNA contribution rather than a  merely reactivation of an 
unstimulated pathway. Similarly, miR-9 and miR-145 showed, also in presence of growth-
stimulating serum concentrations, their capability to reduce cells, confirming that the 
reduction of viability was associated to a reduction of cell proliferation. It is to note that, in 
presence of serum, the inhibitory effect on cell growth resulted to be greater than measured by 
MTS in 0.1% serum. This is presumably due to the positive effect of serum on the growth of 
control cells, but further strengthen the importance of these miRNA level  in the regulation of 
cell proliferation.  
To further validate the data obtained by cell viability evaluation, we analyzed the miRNA 
effect on cell invasiveness using a wound healing assay.  
We chose some  miRNAs on the basis of patient studies and evaluated their effect on cell 
spreading capability. It is to note that such an assay, being performed over 72h after 
transfection, cannot avoid the possibility that cell could proliferate, so in principle this assay 
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does not correctly estimate cell spreading by itself, but the healing can be additively  
influenced by cell number increase. It is also to note that the healing underwent in 0.1% 
serum, a condition that should minimize cell growth. Over the 12  miRNA tested, we have 
seen  that hsa-miR-1307 in MCF01A and T47D increased significantly margin healing in 
addition to stimulate cell growth. Similar results were obtained with miR-210 in MCF-7 and 
HBL100, miR-148 in MCF10A, miR-130b in HBL100 and SKBR3, and miR-21 in MDA-
MB-231. It is to note that miR-210 in ZR75.1 and miR-148 in MCF-7 and MDA-MB-453, 
although having had a stimulatory effect in cell viability, decreased wound healing, indicating 
that the miRNA effect on proliferation can be disjointed from the effect on migration, and that 
the same miRNA can have different effects on different cell lines. In a similar way, two 
miRNA, miR-126 in MB-453 and miR-10 in HBL100, although having an inhibitory effect 
on viability,  showed to be able to stimulate cell migration, suggesting that migration can 
occur also in absence of stimulation of cell proliferation.  Finally, miR-9 in MCF-7 and  miR-
148 in MDA-MB-468 showed to be able to reduce, besides to cell viability, also  cell 
migration. 
 
In addition to data on cell viability, proliferation and invasiveness, to get more insight on the 
role of miRNA cell lines viability regulation, we investigated also the effect of miRNA 
administration on cell transcription. We found that miR-21, miR-26, miR-126, miR-130b, 
miR-145 and miR-210 induced in a pool of different cell lines, the transcription of specific set 
of genes, common to all the lineages explored. Among the different results, the miR-145 
induced transcription changes were surely the most interesting. This miRNA, one of the 
strongest inhibitor of cell proliferation, induced both the up-regulation and the down-
regulation of coherent groups of genes. Among the up-regulated genes, there is complete set 
of genes related to immune surveillance stimulation, typical only of this miRNA among all 
the explored ones. This set includes members of MDH I family , like as HLA-A, HLA-B, 
HLA-C, HLA-E, HLA-F, HLA-G,  HLA-H, HLA-J genes. We found also an increase of 
transcription of genes belonging to MDH II family, like as HLA-DRA and HLA-DRB1. Up-
regulated were also several IFN- related genes, like as IFN-dependent proteins related to 
immune response were over-expressed, and STAT1 and 2.  
These up-regulated genes could suggest  an in vivo role for miR-145, but were apparently 
counteracted by the fact that the intersection of the in vitro data with the data obtained from 
patient did not confirm these results. This contradictory findings admits two explanations.  
Firstly, the in vivo pleiotropic alterations occurring in the miRNA web is able to dampen the 
miR-145-induced changes that in vitro can be more easily highlighted. Secondly, the 
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particular structure of the miRNA used for this test could mimic sequence of viral RNA, able 
to stimulate a strong immune response, not actually related to tumor immune-surveillance. To 
explain the in vitro toxicity of miR-145, that clearly cannot depend upon recruitment of 
immune system cells, could  be other up-regulated or down-regulated genes. Among them, we 
could identify up-regulation of XIAP associated factor 1, a gene involved in caspases 
regulation, 4 members of the PARP  family, PARP9, 10, 12 and 14, a mitochondrial 
serine/threonine phosphatase and optineurin, a protein which may utilize tumor necrosis 
factor-alpha or Fas-ligand pathways to mediate apoptosis. In addition to these wide effects on 
transcription up-regulation, miR-145 reduced also the transcription of several genes. Being 
this the most usual action of a miRNA, is not surprising that the number of the down-
regulated genes was found higher than up-regulated ones (453 vs283); consequently is quite 
reasonably  that this wide down-regulation can pleiotropically impair the cell metabolism and 
functions. Anyway we pointed out two major possible routes: 
1) alteration of mitochondrial functions, obtained through impairment of biosynthesis of 
CoA and diminution of level of mRNA for several mitochondrial proteins 
2) impairment of signal transduction machinery, obtained through  down-regulation of 
mRNA for PKA, protein phosphatase 3, MAPK9 and phospholipase C, inositol 
polyphosphate multikinase, cyclin G1 and U2AF 1 
To  further refine the  insights on miRNA-induced gene regulation, we intersected these 
results with the level 3 data of more than 500 breast cancer patients of  the Tissue Cancer 
Genome Atlas, an online available database. The intersection files showed a list of data for 
miR-130b, miR-145 and miR-210:  the shared gene has a p value  given by the product of the 
p value of the intersected genes, whom were chosen at the significance level of 0.05. This 
originated three lists of genes, each one with a p=0,0025. Among them, we have pinpointed as  
genes of outstanding interest, PTEN and DICER1, respectively found in three lineage of 
breast cancer cell lines and in breast cancer samples. 
  
We have also valued the capacity of migration of the cells after the administration of the 
miRNAs proliferating by wound healing assay. MiR-130b in SKBR3 increases the 
proliferation, evaluated by MTS, and increases the migration, evaluated by wound healing 
method. The same result, obtained for miR-130b, is found for miR-210 in MCF7.  
Over-expression of miR-148 in MCF7 increases the proliferation, analyzed by MTS, and 
increases the invasion, evaluated by xCELLigence. The other miRNAs of the group of 
proliferating, miR-1307, give an effect of increase of proliferation and an increase of 
migration in MCF10A and in T47D. The other group of miRNAs inhibiting, when transfected 
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into breast cancer cell lines, give the following result: miR-145, whose endogenous 
expression is absent in almost part of cell lines, except for T47D, BT-474 and MCF10A in 
which is normal level present, once over-expressed in cell lines, decrease viability on five cell 
lines. Among these, MCF7 after miR-145 treatment, shown decrease of viability both with 
MTS assay both with xCELLigence. Mir-126, another miRNA that results down-expressed in 
almost cell lines and in most part of solid tumors, decrease the viability analyzed by MTS in 
five cell lines and also decrease the invasion on MCF7 when tested by xCELLigence. Mir-9 is 
another miRNA that give a strong effect on proliferation; in particular decrease the viability 
tested by MTS, the proliferation tested by xCELLigence system, and decrease the migration 
analyzed by wound healing method, in MCF7. MiR-93 was analyzed only by MTS assay, and 
shown a decrease on viability in five cell lines. 
Despite that certain miRNAs are over-expressed in cancer cells, the vast majority seems to be 
down-regulated in tumors. 
PTEN is a phosphatase that catalyzed the conversion of the lipid second messenger 
PtdIns(3,4,5)P3 to phosphatidylinositol (4,5)-bisphosphate (PtdIns(4,5)P2). PTEN mutations 
occur frequently in a variety of human cancers. We can see a non-synonymous mutation of 
PTEN only in MDA-MB-453. PTEN has been reported to be regulated by a variety of 
miRNAs, such as miR-21, miR-22, and miR-26a (87). We have found that PTEN is down-
regulated in breast cancer patients with high level of miR-210 and in breast cancer cell lines 
treated with miR-210.  
Aberrant miR-9 levels have been reported in many types of cancer, suggesting that miR-9 is 
involved in tumor formation or progression. We have evaluated the miRNAs levels by 
microarray in some breast cancer cell lines. MiR-9 level is absent in MCF7, MDA-MB-231, 
SKBR3, it is normal level in T47D, BT474, MDA-MB-468 and MDA-MB-453. MiR-9 level 
is nearly high expressed in MCF10A. Over-expression of miR-9 in breast cancer cell lines, 
yield a decrease of viability in MCF7, HBL100, MDA-MB-468 and MCF10A, and also 
produce a reduced capacity of migration in MCF7 when analyzed by wound healing assay and 
by eXCELLigence RTCA system.  A similar result is reported in human neuroblastoma and 
medulloblastoma cells, where the over-expression of miR-9 inhibits cell growth (88, 89) and 
mir-9 expression is also significantly lower in metastatic than primary brain tumors.  
The analysis of patients with different types of breast cancer and of breast cancer cell lines 
treated with miR-130b, shown that Dicer1 is one gene that is down regulated. Dicer1 is a 
ribonuclease type III, that is required for the post-transcriptional processing of miRNAs to 
their mature, functionally active form. In fact, the global miRNA levels are often reduced in 
human tumor specimens and Dicer has been identified as a tumor suppressor gene. The 
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primary tumor development is accelerated when the miRNA biogenesis machinery 
components are inhibited (90). 
 
 
Conclusion 
 
In my thesis, I investigated the possible causal role of microRNAs associated to breast cancer. 
Seven miRNAs which were down-regulated in tumors from breast cancer patients had also a 
repressive effect on cell viability: hsa-miR-326, hsa-miR-145, hsa-miR-126, hsa-miR-28-5p, 
hsa-miR-206, hsa-miR-203, and hsa-miR-181a. 
On the other hand, three miRNAs which were up-regulated in human tumors had a positive 
effect on cell viability in vitro: hsa-miR-210, hsa-miR-130b, hsa-miR-26b. 
Furthermore, I investigated the in vitro activity of miRNAs which are related to patient 
prognosis. The assumption was that these miRNAs would be involved in tumor cell 
proliferation and survival. Four miRNAs which were negatively affecting prognosis activated 
cell viability in vitro: miR-148b, miR-484, miR-615, miR-1307. 
Finally, I can conclude that using breast cancer cell lines I was able to dissect and prioritize 
the functional role of miRNAs associated to cancer. 
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Supplementary Information 
 
Table S1. Breast cancer and normal breast cell lines with the ERα (estrogen receptor), PR 
(progesterone receptor), HER2 (human epidermal receptor 2) status: + positive, - negative; 
TP53 wt (wild type), mut (mutate), and tumorigenic potential 
 
Cell line ERα status PR status HER2 status TP53 Tumorigenic 
MCF-7 + + + wt yes 
MDA-MB-231 - - - mut yes 
MDA-MB-468 - - - mut yes 
MDA-MB-361 + + + mut yes 
SKBR3 - - + mut yes 
T47D + + - mut yes 
BT474 + + + wt yes 
ZR75.1 + + - wt yes 
MDA-MB-453 - - + mut no 
HBL-100 - - + wt yes 
184A1 - - - wt no 
MCF10A - - - wt no 
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Table S2. The genes, the chromosome number, the full name and a short description, for 
which were analyzed the mutation status by Ion Torrent PGM.     
 
Gene Chromosome Official full name Description 
MTOR chr1 mechanistic target of 
rapamycin 
(serine/threonine kinase) 
The protein encoded by this gene belongs to a family 
of phosphatidylinositol kinase-related kinases. These 
kinases mediate cellular responses to stresses such as 
DNA damage and nutrient deprivation 
MPL chr1 myeloproliferative 
leukemia virus oncogene 
The gene c-mpl encoded a protein homologous with 
members of the hematopoietic receptor superfamily. 
NRAS chr1 neuroblastoma RAS viral 
(v-ras) oncogene 
homolog 
This is an N-ras oncogene encoding a membrane 
protein that shuttles between the Golgi apparatus and 
the plasma membrane.  
ALK chr2 anaplastic lymphoma 
receptor tyrosine kinase 
This gene encodes a receptor tyrosine kinase, which 
belongs to the insulin receptor superfamily. 
SF3B1 chr2 splicing factor 3b, 
subunit 1, 155kDa 
This gene encodes subunit 1 of the splicing factor 3b 
protein complex. Splicing factor 3b, together with 
splicing factor 3a and a 12S RNA unit, forms the U2 
small nuclear ribonucleoproteins complex (U2 
snRNP). 
IDH1 chr2 isocitrate dehydrogenase 
1 (NADP+), soluble 
The protein encoded by this gene is the NADP(+)-
dependent isocitrate dehydrogenase found in the 
cytoplasm and peroxisomes. 
ERBB4 chr2 v-erb-b2 avian 
erythroblastic leukemia 
viral oncogene homolog 
4 
This gene is a member of the Tyr protein kinase 
family and the epidermal growth factor receptor 
subfamily. It encodes a single-pass type I membrane 
protein with multiple cysteine rich domains, a 
transmembrane domain, a tyrosine kinase domain, a 
phosphotidylinositol-3 kinase binding site and a PDZ 
domain binding motif. The protein binds to and is 
activated by neuregulins and other factors and induces 
a variety of cellular responses including mitogenesis 
and differentiation. 
MLH1 chr3 mutL homolog 1 This gene was identified as a locus frequently mutated 
in hereditary nonpolyposis colon cancer (HNPCC). It 
is a human homolog of the E. coli DNA mismatch 
repair gene mutL. 
CTNNB1 chr3 catenin (cadherin-
associated protein), beta 
1, 88kDa 
The protein encoded by this gene is part of a complex 
of proteins that constitute adherens junctions (AJs). 
AJs are necessary for the creation and maintenance of 
epithelial cell layers by regulating cell growth and 
adhesion between cells. The encoded protein also 
anchors the actin cytoskeleton and may be responsible 
for transmitting the contact inhibition signal that 
causes cells to stop dividing once the epithelial sheet is 
complete. 
PIK3CA chr3 phosphatidylinositol-4,5-
bisphosphate 3-kinase, 
catalytic subunit alpha 
Phosphatidylinositol 3-kinase is composed of an 85 
kDa regulatory subunit and a 110 kDa catalytic 
subunit. The protein encoded by this gene represents 
the catalytic subunit, which uses ATP to 
phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. 
This gene has been found to be oncogenic and has 
been implicated in cervical cancers. 
FGFR3 chr4 fibroblast growth factor 
receptor 3 
This gene encodes a member of the fibroblast growth 
factor receptor (FGFR) family. 
PDGFRA chr4 platelet-derived growth 
factor receptor, alpha 
polypeptide 
This gene encodes a cell surface tyrosine kinase 
receptor for members of the platelet-derived growth 
factor family. This gene plays a role in organ 
development, wound healing, and tumor progression. 
Mutations in this gene have been associated with 
idiopathic hypereosinophilic syndrome, somatic and 
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familial gastrointestinal stromal tumors, and a variety 
of other cancers.  
KIT chr4 v-kit Hardy-Zuckerman 4 
feline sarcoma viral 
oncogene homolog 
This gene encodes the human homolog of the proto-
oncogene c-kit. C-kit was first identified as the cellular 
homolog of the feline sarcoma viral oncogene v-kit. 
This protein is a type 3 transmembrane receptor for 
MGF (mast cell growth factor, also known as stem cell 
factor).  
KDR chr4 kinase insert domain 
receptor (a type III 
receptor tyrosine kinase) 
Vascular endothelial growth factor (VEGF) is a major 
growth factor for endothelial cells. This gene encodes 
one of the two receptors of the VEGF. This receptor, 
known as kinase insert domain receptor, is a type III 
receptor tyrosine kinase. It functions as the main 
mediator of VEGF-induced endothelial proliferation, 
survival, migration, tubular morphogenesis and 
sprouting.  
FBXW7 chr4 F-box and WD repeat 
domain containing 7, E3 
ubiquitin protein ligase 
This gene encodes a member of the F-box protein 
family which is characterized by an approximately 40 
amino acid motif, the F-box. The F-box proteins 
constitute one of the four subunits of ubiquitin protein 
ligase complex called SCFs (SKP1-cullin-F-box), 
which function in phosphorylation-dependent 
ubiquitination. 
APC chr5 adenomatous polyposis 
coli 
This gene encodes a tumor suppressor protein that acts 
as an antagonist of the Wnt signaling pathway. It is 
also involved in other processes including cell 
migration and adhesion, transcriptional activation, and 
apoptosis. Defects in this gene cause familial 
adenomatous polyposis (FAP), an autosomal dominant 
pre-malignant disease that usually progresses to 
malignancy.  
CSF1R chr5 colony stimulating factor 
1 receptor 
The protein encoded by this gene is the receptor for 
colony stimulating factor 1, a cytokine which controls 
the production, differentiation, and function of 
macrophages. The encoded protein is a tyrosine kinase 
transmembrane receptor and member of the 
CSF1/PDGF receptor family of tyrosine-protein 
kinases. 
NPM1 chr5 nucleophosmin 
(nucleolar 
phosphoprotein B23, 
numatrin) 
This gene encodes a phosphoprotein which moves 
between the nucleus and the cytoplasm. The gene 
product is thought to be involved in several processes 
including regulation of the ARF/p53 pathway.  
EGFR chr7 epidermal growth factor 
receptor 
The protein encoded by this gene is a transmembrane 
glycoprotein that is a member of the protein kinase 
superfamily. This protein is a receptor for members of 
the epidermal growth factor family. EGFR is a cell 
surface protein that binds to epidermal growth factor. 
Binding of the protein to a ligand induces receptor 
dimerization and tyrosine autophosphorylation and 
leads to cell proliferation. 
MET chr7 met proto-oncogene The proto-oncogene MET product is the hepatocyte 
growth factor receptor and encodes tyrosine-kinase 
activity. The primary single chain precursor protein is 
post-translationally cleaved to produce the alpha and 
beta subunits, which are disulfide linked to form the 
mature receptor. 
SMO chr7 smoothened, frizzled 
family receptor 
The protein encoded by this gene is a G protein-
coupled receptor that interacts with the patched 
protein, a receptor for hedgehog proteins. The encoded 
protein tranduces signals to other proteins after 
activation by a hedgehog protein/patched protein 
complex.  
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BRAF chr7 v-raf murine sarcoma 
viral oncogene homolog 
B 
This gene encodes a protein belonging to the raf/mil 
family of serine/threonine protein kinases. This protein 
plays a role in regulating the MAP kinase/ERKs 
signaling pathway, which affects cell division, 
differentiation, and secretion.  
EZH2 chr7 enhancer of zeste 
homolog 2 (Drosophila) 
This gene encodes a member of the Polycomb-group 
(PcG) family. PcG family members form multimeric 
protein complexes, which are involved in maintaining 
the transcriptional repressive state of genes over 
successive cell generations. 
FGFR1 chr8 fibroblast growth factor 
receptor 1 
The protein encoded by this gene is a member of the 
fibroblast growth factor receptor (FGFR) family, 
where amino acid sequence is highly conserved 
between members and throughout evolution. 
JAK2 chr9 Janus kinase 2 This gene product is a protein tyrosine kinase involved 
in a specific subset of cytokine receptor signaling 
pathways. It has been found to be constituitively 
associated with the prolactin receptor and is required 
for responses to gamma interferon.  
CDKN2A chr9 cyclin-dependent kinase 
inhibitor 2A 
This gene is frequently mutated or deleted in a wide 
variety of tumors, and is known to be an important 
tumor suppressor gene. 
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Table  S3. The list of all miRNA tested in the correspondent cell lines. 
 
ZR75.1  MCF7  HBL100 BT474 184A1 
MCF10
A 
MDA-
MB-453 SKBR3 
MDA-
MB-231 
MDA-
MB-468 T47D 
MDA-
MB-361 
Tot. 
 
Cell lines 
 
responsive 
             
  
 
  
             
  
hsa-miR-21                 *       1 
hsa-miR-26b                 *       2 
hsa-miR-99a                         4 
hsa-miR-126*                 *       1 
hsa-miR-130b     *           *       5 
hsa-miR-138   *           * * *     5 
hsa-miR-142-
5p                         0 
hsa-miR-143       *                 2 
hsa-miR-202                         1 
hsa-miR-203                         1 
hsa-miR-210   * *                   5 
hsa-miR-222                         1 
hsa-miR301a                         1 
hsa-miR-302a                         1 
hsa-let-7d*     *                   1 
hsa-miR-145   *         *           5 
hsa-miR-28-5p             *           2 
hsa-miR-33b                         1 
hsa-miR-126   *         *           5 
hsa-miR-181a   *     *         *     3 
hsa-miR-202                         1 
hsa-miR-203         *       *       3 
hsa-miR-206           * *           2 
hsa-miR-302a             *           1 
hsa-miR-326 *           *           2 
hsa-miR-484     *                   1 
 
MiRNA having an outlier 2 effect, e.g. whose effect was greater (red boxes) or lower (green 
boxes) than median plus or minus 2 MAD, as reported in M&M. The star indicates which 
among miRNA shows also an outlier 3 effect. The miRNA name in bold indicates that 
miRNA is up-regulated in solid tumor 
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ZR75.1  MCF7  HBL100 
MDA-
MB-361 184A1 MCF10A 
MDA-
MB-453 SKBR3 
MDA-
MB-231 
MDA-
MB-468 T47D Tot 
       
 
    
cell lines 
 
 responsive 
       
 
    
  
hsa-miR-9   *     nd *           5 
hsa-miR-10a               *       2 
hsa-miR-25                       1 
hsa-miR-27         nd   *         2 
hsa-miR-30a                       2 
hsa-miR-93     * nd       *       5 
hsa-miR-103     * nd               2 
hsa-miR-
148b *         * *       * 5 
hsa-miR-151                       0 
hsa-miR-
301a          nd     *       3 
hsa-miR-328                       0 
hsa-miR-484                        2 
hsa-miR-615   *     nd *       *   4 
hsa-miR-874       nd               2 
hsa-miR-
1307         * *           5 
 
Table S4. In table are reported all the miRNA tested in the cell lines. MiRNA having an outlier 2 effect, e.g. whose effect was greater (red boxes) or 
lower (green boxes) than median plus or minus 2 MAD 
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Table S5. Table reports the wound healing assay 
 
. ZR75.1  MCF7  HBL100 MCF10A MDA-MB-453 SKBR3 MDA-MB-231 MDA-MB-468 T47D 
     
 
    
 
 
     
 
    hsa-miR-9 nd ↓ nd nd nd nd nd nd nd 
hsa-miR-10a nd nd ↓ nd nd nd nd   nd 
hsa-miR-21 nd nd nd nd nd nd  ↑ nd nd 
hsa-miR-26 nd   nd   nd nd nd ↑ nd 
hsa-miR-99 nd nd nd ↑ nd nd nd nd   
hsa-miR-126 nd nd nd nd ↓ nd nd nd nd 
hsa-miR-130b ↑ ↑   nd nd  ↑ ↑ nd   
hsa-miR-138 nd nd nd nd nd ↑ nd nd ↑ 
hsa-miR-148 ↑ ↑ nd  ↑ ↑ nd nd ↓ ↑ 
hsa-miR-210 ↑  ↑   nd nd nd   ↑ nd 
hsa-miR-222 nd nd nd nd ↑ nd nd nd nd 
hsa-miR-1307 nd   nd  ↑ nd nd nd nd  ↑ 
 
In red are shown the miRNAs that gave a significant (t testp<0.05) increase of migration when analyzed by wound healing assay, in green the 
miRNAs that give a significant (t testp<0.05) decrease of migration. In blank  are indicated the miRNAs that do not give any effect on migration. nd 
= not done. Arrows refer to significant changes in cell viability measured with MTS assy: ↑ viability increase; ↓ viability decreas
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miR-210 
 
miR-
130b 
ABAT ACADSB 
ABCC3 ADCY1 
ABHD6 AIG1 
ADIPOR2 ANXA9 
AGL AREG 
AKAP2 ARL3 
AKAP9 C14orf45 
ANK3 C2orf15 
ANKS1B C7orf63 
ARHGAP12 CCDC146 
ARHGAP18 CD44 
ARHGAP32 CDS1 
ARHGEF12 CELSR2 
ARHGEF38 CLCN3 
ARID2 CLSTN2 
ARRDC4 CPPED1 
ATP7A CYB5D1 
BAZ2B DCDC2 
BBX DHRS2 
BCKDHB DHX40 
BHLHE41 DICER1 
BTN3A1 DYNLRB2 
BTN3A3 EEF2 
C12orf35 EFHC1 
C20orf96 ELOVL2 
C7orf63 EML1 
CD59 ENPP4 
CDS1 FBXL17 
CGN FHL2 
CHD6 FLJ42627 
CHM GDAP1 
CMYA5 GPR39 
COL4A3BP GREB1 
COMMD10 IFT122 
CPEB2 IFT46 
CPNE8 IRX3 
DDB2 ITGB5 
DOCK8 ITPK1 
DUSP16 KATNAL1 
EFEMP1 LDLRAD3 
ELF1 LMLN 
ELOVL2 LONP2 
EPB41L5 LPGAT1 
EPM2AIP1 LRRC49 
ERAP1 MACF1 
FAM102A MEF2C 
FAM126A MGMT 
FGD4 MTL5 
FIG4 MTX3 
GLCE MYB 
GLRB NBPF22P 
GPD1L NBPF4 
GRAMD1C NBPF6 
HMCN1 NCKAP5 
HOXC6 NPY1R 
ICA1L NR1D2 
IFIT5 NRIP1 
INHBB PAN3 
ITPR2 PCNX 
JMJD1C PDZK1 
KIF16B PDZK1P1 
KITLG PLA2G12A 
KLF8 PNMA1 
KLHL2 PNPO 
KLHL5 PTGR2 
KLHL9 PTPRG 
LASP1 RAB31 
LIMA1 SBF2 
LIPH SCUBE2 
LNPEP SETD7 
LOC202781 SLC22A5 
LOC374443 SLC4A7 
LPGAT1 SNX24 
LPIN2 SPA17 
LRBA SPATA6 
MAST4 SPRY2 
MBNL2 STXBP4 
MECOM SYTL5 
MED13L TEX2 
MET TEX9 
MGP TGFBR2 
MMP16 TMEM67 
MPP7 TOM1L1 
MSI2 TRIM45 
MYCBP2 TRIM68 
MYO5C TSHZ1 
MYO6 UHMK1 
MYOF VTCN1 
NCKAP5 WDR19 
NCOA2 WDR35 
NFIC WDR52 
NR1D2 WRN 
NSF ZNF185 
PAIP2B ZNF418 
PARP4 ZNF559 
PBX1 ZNF594 
PDE5A 
 PDZK1 
 PDZK1P1 
 PER3 
 PHF11 
 PIK3C2A 
 PION 
 PJA2 
 PKD2 
 PLA2R1 
 PLK2 
 PPP1R9A 
 PRLR 
 PROS1 
 PTEN 
 PTPN21 
 PTPRG 
 RAB27B 
 RAB8B 
 RAPGEF6 
 RBL2 
 RBPMS 
 RICTOR 
 RNF43 
 RSC1A1 
 SAMD12 
 SCARA3 
 SEMA3C 
 
SETBP1 
 SH3D19 
 SHROOM3 
 SIDT2 
 SLC26A2 
 SLC35A3 
 SMPDL3A 
 SP100 
 SPIN3 
 SPRED2 
 SRGAP1 
 SYTL2 
 SYTL5 
 TBC1D9 
 TET2 
 TEX9 
 THBS1 
 TMEM117 
 TMEM144 
 TMEM154 
 TMTC2 
 TP53BP1 
 TRAK2 
 TRANK1 
 TRIB1 
 TRIM44 
 TRIM5 
 TSPAN1 
 TTC21B 
 UTRN 
 VPS13C 
 WDR44 
 WDR52 
 ZBTB38 
 ZHX2 
 ZNF134 
 ZNF224 
 ZNF772 
 ZNF827 
 
 
Table S6. In the table the genes that are negatively regulated in breast cancer tumors and in breast 
cancer cell lines transfected with miR-210 and miR-130b.  
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Figure S1. the experiments of wound healing assay, for the indicated cell lines and miRNAs. 
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